PATIENT-REPORTED OUTCOMES ‘PRO’ SYMPOSIUM
CONCEPTUAL AND METHODOLOGICAL ISSUES

Hyatt Regency Crystal City, Arlington, Virginia, USA
Prior to the ISPOR 7th Annual International Meeting

Sunday, May 19, 2002  6:30 – 8:30 pm
Followed by a Reception
Sponsored by: ISPOR and PhRMA Health Outcomes Committee
This program was developed in cooperation with the Patient-Reported Outcomes Harmonization Group*

Background:
Data to evaluate the efficacy or effectiveness of treatment can come from a variety of sources, including laboratory tests, clinician evaluation, and the patients themselves. In the outcomes research community, the term “patient-reported outcomes (PRO)” is used to refer to a host of outcomes that can be provided only by the patient. Examples of these outcomes include symptom severity, perception of daily functioning, feelings of well being, global impressions of the impact of treatment on daily life, satisfaction with treatment, and health-related quality of life. The role that PROs can and should play in evaluating the efficacy of pharmaceuticals and medical devices and the means by which these outcomes are communicated to clinicians and consumers are subjects of much discussion and debate.

Over the past 2 years, representatives from ISPOR, PhRMA HOC, ISOQOL and ERIQA (now collectively called the *Patient-Reported Outcomes (PRO) Harmonization Group) have been participating in discussions with the FDA about the use of health-related quality of life (HRQL) and, more recently, patient reported outcomes (PRO) in pharmaceutical research and communications. An overview of PRO Harmonization Group initiatives, meetings, presentations are at the PRO Harmonization Group website at www.pro-harmonization-group.com. This symposium will highlight activities of the PRO Harmonization Group, and provide an overview of discussions related to conceptual and methodological issues with specific examples.

PROGRAM

6:30 – 6:40 PM  INTRODUCTION & OVERVIEW OF THE PRO HARMONIZATION GROUP EFFORTS
Speaker & Moderator: Jean Paul Gagnon PhD, Director, Public Policy, Aventis Pharmaceuticals, Bridgewater, NJ, USA

6:40 – 6:55 PM  ‘PRO’ CONCEPTUAL ISSUES
Speaker: Margaret Rothman PhD, Executive Director, Health Economics Johnson and Johnson Pharmaceutical Research and Development, Raritan, NJ, USA

6:55 – 7:10 PM  ‘PRO’ METHODOLOGICAL ISSUES
Speaker: Nancy Santanello MD, MS, Executive Director, Epidemiology, Merck Research Laboratories, West Point, PA, USA

7:10 – 7:40 PM  SPECIFIC FDA ISSUES
7:10 – 7:25 PM  **INSTRUMENT DEVELOPMENT: WHAT ARE THE STANDARDS? 
Speaker: Donald Patrick PhD, MSPH, Professor, University of Washington, Seattle, WA, USA
7:25 – 7:40 PM  ** INTERPRETING CHANGES THAT ARE NOT CONSISTENT BETWEEN OUTCOMES
Speaker: Nancy Kline Leidy PhD, Vice President & Director of the Center for Health Outcomes Research, MEDTAP International, Bethesda, MD, USA

7:40 – 8:00 PM  FDA PERSPECTIVE OF ‘PRO’
Speaker: Laurie Beth Burke Rph, MPH, Chief, Regulatory Review Branch, FDA, CDER, DDMAC, Rockville, MD, USA

8:00 – 8:30 PM  PANEL AND AUDIENCE DISCUSSION

8:30 – 9:30 PM  RECEPTION

Continuing Education Credit

For pharmacists (CPE): Continuing education credits for pharmacists will be provided by Butler University. Butler University designates this continuing pharmaceutical education activity for 18 hours (1.8CEUs) for the Annual Meeting and 4 hours (.4CEUs) for each Short Course. Butler University is approved by the American Council of Pharmaceutical Education as a provider of continuing pharmaceutical education.

For physicians (CME): ISPOR provides documentation for Physician-designated American Medical Association (AMA) Physician’s Recognition Award Category 2 continuing medical education (CME) credit. This ISPOR 6th Annual International Meeting program complies with the AMA’s definition of CME, with AMA ethical opinions on Gifts to Physicians from Industry and on Ethical Issues in CME. Up to 18 hours (1.8CEUs) for the Annual Meeting and 4 hours (.4 CEUs) for each Short Course can be designated. ISPOR is not accredited by the Accreditation Council for Continuing Medical Education.
ANNUAL MEETING PLANNING COMMITTEE

General Chair: Peter Neumann ScD, Assistant Professor of Policy & Decision Sciences, Harvard School of Public Health, Boston, MA, USA
Plenary Session Committee Chair: Louis Morris PhD, President, Louis A. Morris & Associates, Dix Hills, NY, USA
Issue Panels Committee Chair: Josephine Mauskopf PhD, Executive Director, RTI Health Solutions, Research Triangle Park, NC, USA
Contributed Research Review Committee Chair: Kathryn Phillips PhD, Associate Professor of Health Economics and Health Services Research, University of California-San Francisco, CA, USA

CONTRIBUTED RESEARCH ABSTRACT REVIEW COMMITTEE

Berhanu Alemayehu DrPH, MS, Merck-Medco Managed Care, Franklin Lakes, NJ, USA
Charles Alexander MD, Merck & Co, Inc., West Point, PA, USA
Mayur Amonkar MS, PhD, West Virginia University, Morgantown, WV, USA
Talat Ashraf MD, MS, Abbott Laboratories, Abbott Park, IL, USA
Alan Bakst PharmD, RPh, MS, GlaxoSmithKline, Collegeville, PA, USA
Mohan Bala PhD, Centocor Inc., Malvern, PA, USA
Rajesh Balkrishnan PhD, MS, Wake Forest University School of Medicine, Winston-Salem, NC, USA
Judith Bentkover PhD, Innovative Health Solutions, Brookline, MA, USA
Richard Berzon DrPH, Boehringer Ingelheim, Ridgefield, CT, USA
Jennie Best MA, Acumen LLC, Burlington, MA, USA
Susan Blalock PhD, University of the Pacific, Stockton, CA, USA
Philip Booth MS, Novartis Pharmaceuticals, Framingham, MA, USA
Joseph C. Cappelleri PhD, MPH, Pfizer Inc, Groton, CT, USA
Chih-Hung Chang PhD, Evanston Northwestern Healthcare, Evanston, IL, USA
Chiu-Fang Chiou MS, MA, PhD, Zynx Health Incorporated, Beverly Hills, CA, USA
Douglas Coyle MA, MSC, Loeb Research Institute, Ottawa, Ontario, Canada, USA
Caro Research Institute, Concord, MA, USA
J. Jaime Caro MD, Caro Research Institute, Concord, MA, USA
Mayur Amonkar MS, PhD, West Virginia University, Morgantown, WV, USA
Aaron Davis PhD, Research Triangle Institute, Research Triangle Park, NC, USA
Jeffrey Deo RPh, PhD, University of Pittsburgh, Pittsburgh, PA, USA
Joseph Menzin PhD, Boston Health Economics, Inc., Waltham, MA, USA
Penny Mohr PhD, Project Hope, Bethesda, MD, USA
C. Daniel Mullins PhD, University of Maryland, School of Pharmacy, Baltimore, MD, USA
David Nau RPh, PhD, University of Michigan, Ann Arbor, MI, USA
Les Nee RPh, MPA, Ovation Research Group, Highland Park, IL, USA
Mark Nijsten MD, MBA, MEDTAP International, Jisp, The Netherlands
Judith O’Brien RN, BSPA, Caro Research, Concord, MA, USA
Frank Papatheofanis PhD, MD, UCSF, San Diego, CA, USA
Chris L. Pashos PhD, Abt Associates Clinical Trials, Cambridge, MA, USA
John E. Paul PhD, RTI Health Solutions, Research Triangle Park, NC, USA
Andrew Pleil PhD, Pharmacia & Upjohn, Stockholm, Sweden
Ateequr Rahman MBA, PhD, St. John’s University, Jamaica, NY, USA
Prabhshnde Reddy PharmD, University of Connecticut, Hartford, CT, USA
Gene Reeder PhD, University of South Carolina, Columbia, SC, USA
Anne Rentz MSPH, MEDTAP International, Inc, Bethesda, MD, USA
Anke Richter PhD, Research Triangle Institute, Research Triangle Park, NC, USA
Andrew Rosner BSc, MBA, Innovus Research Inc, Burlington ON, Canada
Professor Reinhard Rychlik MA, MD, PhD, Institute of Empirical Health Economics, Burscheid, Germany
Kay Sadik PharmD, PhD, Janssen Pharmaceutica, Irvine, CA, USA
Pierre-Philippe Sagnier MD, MPH, Bayer Pharma, Slough, United Kingdom
Gerald Schumacher, Northeastern University, Boston, MA, USA
Hemal Shah PharmD, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA
Mendel Singer PhD, Case Western Reserve University, Cleveland, OH, USA
Dean Smith PhD, University of Michigan, Ann Arbor, MI, USA
James Stevenson PharmD, University of Michigan Health Systems, Ann Arbor, MI, USA
Bradley Stolshek PharmD, Amgen, Inc., Thousand Oaks, CA, USA
Dong-Churl Suh MBA, PhD, College of Pharmacy, Rutgers University, Piscataway, NJ, USA
Kent Summers RPh, PhD, Eli Lily & Company, Indianapolis, IN, USA
Yen-Hui Tarn PharmD, School of Pharmacy, National Defense Medical Center, Taipei, Taiwan
David Thompson PhD, Innovus Research Inc, Medford, MA, USA
George Torrance PhD, Innovus Research Inc., Burlington, Ontario, Canada
Daniel Touchette BSc, PharmD, OSU College of Pharmacy, Clackamas, OR, USA
Samuel Wagner PhD, RPh, Pharmacia Corporation, Cottage Grove, MN, USA
Fang Wang MD, PhD, Wyeth-Ayerst Research, Radnor, PA, USA
Andrew Wang MD, PhD, Pfizer Pharmaceutical Group, Ann Arbor, MI, USA
Greg Zaric PhD, University of Western Ontario, London, ON, Canada
Arthur Zbrozek MS, MBA, Wyeth-Ayerst Research, Philadelphia, PA, USA

Contributed Workshop Review Committee

Maiwenn J. Al PhD, IMTA, Erasmus University, Rotterdam, The Netherlands
Lieven J.P. Annemans PhD, MMan, MSc, HEDM, Meise, Belgium and Brussels Free University, Brussels, Belgium
Judith Barr ScD, Northeastern University, Boston, MA, USA
J. Jaime Caro MD, Caro Research Institute, Concord, MA, USA
Newell McElwee PharmD, MSPH, Pfizer, Inc., New York, NY, USA
SATURDAY, MAY 18TH, 2002

ALL DAY SESSION (9:00AM-5:00PM)

Pharmacoeconomics for the Healthcare Decision Maker
Lorne E. Basskin PharmD, Associate Professor, College of Pharmacy and Health Sciences, Butler University, IN, USA

Course Description: This one-day short course is designed to teach clinicians and new researchers how to incorporate pharmacoeconomics into study design and data analysis. Participants will learn how to collect and calculate the costs of different alternatives, determine the economic impact of clinical outcomes, and how to identify, track and assign costs to different types of health care resources used. The development of economic protocols and data collection sheets will be discussed. Different pharmacoeconomic models and techniques will be demonstrated and practiced in lectures and case studies. These include cost-minimization, cost-of-illness, cost-effectiveness, cost-benefit, and cost-utility analysis. Decision analysis, sensitivity analysis, and discounting, will all be demonstrated and practiced. Participants will also learn to compare and evaluate interventions such as drugs, devices and clinical services. This course is suitable for those with little or some experience with pharmacoeconomics.

SUNDAY, MAY 19TH, 2002

MORNING SESSION (8:00AM-12:00PM)

Meta-Analysis and Systematic Literature Review – Introduction
Joseph C. Cappelleri PhD, MPH, Associate Director, Pfizer Inc., CT, USA and Joseph Lau MD, New England Medical Center and Tufts University Medical School, MA, USA

Course Description: Meta-analysis may be defined as the statistical analysis of data from multiple studies for the purpose of synthesizing and summarizing results, as well as for quantitatively evaluating sources of heterogeneity and bias. A systematic literature review often includes meta-analysis and involves an explicit, detailed description of how a review was conducted. This short course highlights and expounds upon four key areas: 1) impetus for meta-analysis and systematic reviews, 2) basic steps to perform a quantitative systematic review, 3) statistical methods of combining data, and 4) appraisal and use of meta-analytic reports. The material is motivated via applications in pharmacoeconomics, outcomes research, and clinical studies from the published literature and hypothetical examples. Interactive exercises are part of the course. After attending the workshop, participants should be able to 1) express the need for meta-analysis and systematic literature review, 2) describe the basic steps to perform a quantitative systematic review, 3) explain statistical methods of combining data, and 4) appraise meta-analytic reports and decide whether to use their results. This course is designed for those with little experience with meta-analysis.

Introduction to Patient Reported Outcomes (PRO) Assessment: Designing a PRO Strategy
Linda Abetz MA, Project Director, Mapi Values, UK

Course Description: Conceptual, methodological, and practical methods for measuring patient reported outcomes. An emphasis will be placed on health-related quality of life, with additional discussion provided on symptom and treatment satisfaction assessment strategies. A strategy to aid in selecting appropriate instruments will be presented. Reliability, validity, responsiveness, methods of administration and scoring, and issues of analysis and interpretation will be discussed using practical examples and exercises. This course is designed for those with either little or intermediate experience in health-related quality-of-life assessment.

Statistics for Non-Statisticians
Thomas Einarson PhD, Associate Professor, Faculty of Pharmacy, University of Toronto, Toronto, Canada

Course Description: This course is designed to present an overview of the foundations upon which major statistical tests are based and tests which may be used to address pharmacoeconomic problems. The major emphasis will be on application and interpretation of statistical results, not statistical theory. Surveyed will be the most commonly utilized statistical tests (t-test, ANOVA, correlation, regression, chi square) and the types of variables associated with each test. The course will assist ISPOR attendees who are interested in increasing their understanding of the general principles associated with elementary statistics and how to apply these tests to problems presented in their work environment. This course is suggested as a prerequisite to "Statistical Considerations in Pharmacoeconomic Evaluations – Advanced" for those who lack a background in basic inferential statistics or need a brief review.

Decision Analysis – Introduction
Mark Roberts MD, MPP, FACP, Associate Professor of Medicine, Chief, Section of Decision Sciences and Clinical Systems Modeling, University of Pittsburgh School of Medicine, PA, USA

Course Description: Decision analysis is a tool that provides an explicit structure for solving complicated healthcare problems, and is commonly used as the tool for conducting cost-effectiveness analyses as well. This
course will describe the basic structure and analysis of decision trees, the calculation of expected utilities, sensitivity analysis, the assessment of patient values, and inclusion of quality-of-life parameters. Simple examples will be used to illustrate these concepts, and more complex examples from the literature will be presented. This course is designed for those with little or no experience in decision analysis.

Introduction to Bayesian Approaches to Health Economics and Outcomes Research
Bryan Luce PhD MBA, Senior Research Leader & CEO, MEDTAP International, MD, USA, Tina Shih PhD, Research Scientist, MEDTAP International, MD, USA, Chris M. Barker PhD, Director of Statistical Research, MEDTAP International, MD, USA, Frank E. Harrell, Jr. PhD, Professor of Biostatistics and Statistics, University of Virginia School of Medicine, VA, USA

Course Description: This course is designed to provide an overview of the Bayesian approach and its applications to health economics and outcomes research. The course will cover basic elements of the Bayesian statistics (prior, likelihood, and posterior distribution, conjugate families, EVPI, etc.), discuss differences between Bayesian and classical (Frequentist) approach, and demonstrate how to apply the Bayesian approaches to clinical trials and cost-effectiveness analyses. Studies conducted in Excel or WinBUGS, statistical software designed for Bayesian computations, will be presented as teaching examples. Participants will learn how to interpret and apply the Bayesian approaches to their work. This course is designed for the beginner or intermediate POR professional.

Introduction to Pharmacoepidemiology
David Lilienfeld MD, MS, MPH, Associate Director, Pharmacoepidemiology, Bristol Myers-Squibb, NJ, USA

Course Description: Pharmacoepidemiology is the application of epidemiological knowledge and methods to study the effects (both positive and negative) of drugs in human populations. Its purpose is to describe and predict drug treatment in a defined time, space, and population. This course will provide an overview of the contribution of epidemiology to the study of drug uses and effects. Pharmacoepidemiologic study design strategies (observational, analytic, and intervention studies) including their strengths and weaknesses will be presented. This course is for those with no or little experience with pharmacoepidemiology.

AFTERNOON SESSION (1:00PM-5:00PM)

Decision Analysis - Advanced Applications
Marc F. Botteman MSc, MA, Executive Director, International Health Economics, HEROQuES, Abt Associates Clinical Trials, MD, USA

Course Description: This course will teach participants how to use and implement intermediate-to-advanced decision analysis techniques (such as Markov models and first- and second-order Monte Carlo simulations) for cost-effectiveness analyses. After a brief review of these methods and their appropriate use, the course will focus on the steps involved in developing Markov models and conducting Monte Carlo simulations. To illustrate how these methods are applied, examples will be demonstrated in Microsoft Excel and Monte Carlo simulation software, as appropriate. Issues related to the selection of model input parameters and their distributions for use in probabilistic sensitivity analyses will be reviewed. Participants will learn how to analyze, interpret, and present results (e.g. using acceptability curves or analyses of the cost-effectiveness plane). If time permits, the course will also briefly cover more advanced topics (e.g. discrete event microsimulations). Publications from healthcare journals presenting additional examples and theoretical considerations will be provided as a course supplement. This intermediate course requires basic understanding of decision analysis. Also, because computers are not available for participants' use, please note that the course will be characterized more as seminar-style, rather than as a hands-on modeling workshop.

Elements of Pharmaceutical Pricing
E.M. (Mick) Kolassa PhD, Associate Professor, Pharmacy Administration, University of Mississippi, MS, USA

Course Description: The elements of pharmaceutical pricing decisions and the role of pharmacoconomics in shaping those decisions will be discussed. This course is designed for those with some experience in either pharmacoconomics or pharmaceutical pricing.

Prospective Economic Trials
Gerry Oster PhD, Vice President, Policy Analysis Inc. (PAI), MA, USA

Course Description: Randomized controlled trials are the accepted standard for demonstrating the efficacy and safety of new pharmaceuticals. They also can be a useful venue for collecting economic data. This course will provide participants with an overview of methodologic and practical issues surrounding economic data collection that is "piggybacked" onto otherwise-traditional randomized controlled trials, including protocol development, data collection, and data analysis. The course also will consider circumstances under which such studies do not provide an appropriate setting for collecting "real-world" economic data, and will discuss key aspects of clinical trials that are conducted specifically to inform economic decision making ('"pragmatic clinical trials") as well as issues in the design and conduct of these types of investigations. Course participants will be asked to solve specific problems in the design of trial-based economic investigations. This course is designed for persons with a basic knowledge of and familiarity with clinical trial methodology as well as techniques of economic investigation.

Quality-of-Life – Advanced
Karen F. Gold PhD, Director of Biostatistics and Outcomes Research, Abt Associates Clinical Trials, MD, USA

Course Description: This section will discuss the role of advanced psychometric analysis in the construction and evaluation of quality-of-life instruments. The course will use the latent variable model as an organizing theme around the following approaches to scale evaluation: 1) internal consistency, 2) exploratory factor analysis, 3) confirmatory factor analysis, 4) structural equation models with latent variables and 5) item response modeling. Two detailed worked examples will be presented examining handling loss to follow-up due to death in a QoL study (structural equations model) and adaptive Quality of Life assessment tools (item response theory). This course is for those with experience with quality-of-life instruments and psychometric models.

Advanced Retrospective Database Analyses
Thomas E. Delea MBA, Senior Consultant, Policy Analysis Inc. (PAI), MA, USA

Course Description: Large-scale retrospective databases provide a unique opportunity to examine the effects of drug use on clinical and economic outcomes in "real world" settings. The learning objective for this course will be to gain in-depth understanding and hands-on experience with methods for estimating the relationship between drug use and clinical and economic outcomes using retrospective databases. An overview of the challenges associated with confounding (i.e., selection bias) and censoring in retrospective database analyses will be described, along with general approaches for addressing these challenges including sample selection and analytical approaches. Selected analytical methods will be described including general linear regression, logistic regression, Poisson regression, and Cox proportional hazards regression. Topics to be covered include methods for assessing the degree of confounding, selection of covariates, assessing the appropriateness of model assumptions, incorporating time-dependent covariates, analyzing multiple events per patient, and estimation of adjusted event rates and survival functions. The uses of propensity scores to control for confounding through matching, stratification, or as covariates in multivariate analyses will be examined as well. Specific examples of these various techniques will be provided. Course participants will be asked to participate in a case study in which the methods described in the course will be applied. This course is for persons with a basic understanding of statistics and principles of clinical epidemiology.

Statistical Considerations in Pharmacoeconomic Evaluations – Advanced
Kevin D. Frick PhD, Johns Hopkins Bloomberg School of Public Health, Department of Health Policy and Management, MD, USA

Course Description: This course will provide an overview of the terminology and key methodological features of pharmacoeconomic evaluations. The primary focus will be on the statistical considerations of planning and analyzing studies and interpreting the results, including comparisons of types of analyses used and discussing important study design features for clinical economic trials. Methods of statistical analysis for cost data and for estimating cost-effectiveness ratios will be thoroughly reviewed, making extensive use of real-life examples and published studies. This course is designed for those with experience in conducting pharmacoeconomic studies.
"Bringing Outcomes Research to the Forefront"

SUNDAY, MAY 19, 2002

9:00-10:00 pm  Student Icebreaker & Reception

MONDAY, MAY 20, 2002

7:00-8:00  Early Bird Forum

"AMCP FORMAT FOR FORMULARY SUBMISSIONS: WHO IS USING THEM, WHO WILL BE EVALUATING THEM, AND WHAT REGULATORY CONCERNS DO THEY RAISE"

Since AMCP published its guidance, "A Format for Submission of Clinical and Economic Data in Support of Formulary Consideration by Managed Health Care Systems in the United States", a number of health plans and PBMs have adopted it. This session will focus on how this guidance is being used, who will be evaluating it, and possible regulatory concerns about its use.

Moderator: Dell Mather PharmD, Senior Director, Pharmacotherapy Assessment & Policy, Prime Therapeutics, Inc, St. Paul, MN, USA

Speaker: Peter M. Penna PharmD, President, PM Penna LLC, Seattle, Washington, USA and AMCP Officer

Speaker: Laurie Beth Burke RPh, MPH, Chief, Regulatory Review Branch, FDA, CDER, DDMAC, Rockville, MD, USA

8:00-8:30  Welcome

Peter Neumann ScD, ISPOR Annual Meeting Program Chair and Assistant Professor of Policy & Decision Sciences, Harvard School of Public Health, Boston, MA, USA

Presidential Address

Eva Lydick PhD, ISPOR 2001-2002 President and Director of Epidemiology, AstraZeneca, Wilmington, DE, USA

Presentation: ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Award

8:30-10:00  First Plenary Session

"THE RISE OF NEW FRONTIERS FOR OUTCOMES RESEARCHERS"

Outcomes researchers have become more involved in cutting edge research, whether it be as the interface between clinical and marketing interests in drug companies, advisors regarding the use of Patient Reported Outcomes (PRO) claims in marketing, or as experts regarding the use of pharmacoepidemiological and pharmacoeconomic data in public policy debates. The need to meet foreign standards for reimbursement approval will also be discussed in this session as a new requirement for outcomes researchers. This session will discuss educational and performance challenges for meeting these new opportunities and new roles for outcomes researchers.

Moderator: Eva Lydick PhD, 2001-2002 ISPOR President & Director, Outcomes Research, AstraZeneca, Wilmington, DE, USA

Speaker: Jerome Avorn MD, Associate Professor, Harvard Medical School, Boston, MA, USA

Panelist: Deborah Zarin MD, Director, Technology Assessment Program, Agency for Healthcare Research and Quality, US Department of Health & Human Services, Rockville, MD, USA

Panelist: Edwin Hedblom PharmD, Chief Pharmacy Officer – AARP Pharmacy Division, UnitedHealth Group, Minnetonka, MN, USA

Questions and Audience Participation

10:00-10:30  Exhibits & Poster Presentations – Session I
**CARDIOVASCULAR DISEASE/DISORDERS I**

**CV1**  
**NONCOMPLIANCE WITH STATIN THERAPY: LOST CLINICAL BENEFITS AND IMPLICATIONS FOR COST-EFFECTIVENESS**  
Benner JS, Ganz DA, Weinstein MC, Neumann PJ, Glynn RJ, Avorn J, ‘Brigham and Women’s Hospital / Harvard Medical School, Boston, MA, USA; ‘Harvard School of Public Health, Boston, MA, USA

**CV2**  
**OUTCOMES AND COSTS OF ISCHEMIC COMPLICATIONS AND BLEEDING IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS**  
Delea TE, Plent S, Edelsberg JS, Oster G, ‘PAI, Brookline, MA, USA; ‘The Medicines Company, Cambridge, MA, USA

**CV3**  
**LONG-TERM COSTS AND CLINICAL CONSEQUENCES OF DIFFERENT LEVELS OF 2-HOUR POST PRANDIAL BLOOD GLUCOSE IN NON-DIABETES PATIENTS**  
Palmer AJ, Roze S, Foos V, Lurati FM, Hirini S, CORE Center for Outcomes Research, Basel, Switzerland

**CV4**  
**CORRELATION BETWEEN NEW YORK HEART ASSOCIATION CLASSIFICATION AND PATIENT-REPORTED OUTCOMES**  
Yokoyama KK, Blumenschein K, Johannesson M, Gause D, Frech P, ‘Novartis Pharmaceuticals Corporation/Scott & White Health Plan/University of Texas at Austin, East Hanover, NJ, USA; ‘University of Kentucky College of Pharmacy and Martin School of Public Policy and Administration, Lexington, KY, USA; ‘Stockholm School of Economics, Stockholm, Sweden; ‘Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

**MENTAL HEALTH (Including Dementia)**

**MH1**  
**A ROBUST GLOBAL TREATMENT RESPONSE AVAILABLE TO OLanzAPINE-TREATED PATIENTS IS ASSOCIATED WITH MEANINGFUL IMPROVEMENT IN NEGATIVE SYMPTOMS AND QUALITY OF LIFE**  
Kinon BJ, Phao Z, ‘Lilly Research Laboratories, Indianapolis, IN, USA; ‘Eli Lilly and Company, Indianapolis, IN, USA

**MH2**  
**COMPARISON OF TREATMENT COST FOR DEPRESSION BETWEEN FLUOXETINE, PAROXETINE, SERTRALINE AND VENLAFAXINE USING MANAGED CARE CLAIMS DATA**  
Curkendall SM, Goehring EL, She D, Pezzullo JC, Jones JK, ‘The Degge Group, Ltd, Arlington, VA, USA; ‘Georgetown University, Washington, DC, USA

**MH3**  
**DEPRESSION IN PRIMARY CARE: TREATMENT AND RESPONSE**  
Corey-Lisle PK, Nash R, Stang P, Swindle R, ‘Eli Lilly & Company, Indianapolis, IN, USA; ‘Florida A&M University, Tallahassee, FL, USA; ‘Primary Care Network, Blue Bell, PA, USA

**MH4**  
**ECONOMIC IMPACT OF TREATMENT OF DEMENTIA FOR GERMANY - A PROGNOSES TO 2050**  
Happich M, Hallauer JF, University Clinic Charite, Berlin, Germany

**DIABETES**

**DB1**  
**THE VALUE OF MULTIPLE YEARS HISTORY IN IDENTIFYING COMORBID CONDITIONS IN A RETROSPECTIVE DATA ANALYSIS**  
Morris L, Henderson SC, von Allmen H, Margolis J, IMS Health, Plymouth Meeting, PA, USA

**DB2**  
**QOL INDICATORS OF SATISFACTION AND IMPACT ASSOCIATED WITH WEB-ENABLED DIABETES SELF-MANAGEMENT TOOLS**  
Atherton MP, Becker MA, ‘George Mason University, Fairfax, VA, USA; ‘PDHI, INC, Bernardsville, NJ, USA

**DB3**  
**DIABETIC FOOT ULCERS: THE ECONOMIC CONSEQUENCES OF INPATIENT ADMISSIONS OVER FIVE YEARS**  
O’Brien J, Patrick A, Caro JJ, Caro Research Institute, Concord, MA, USA

**DB4**  
**A SYSTEMATIC ANALYSIS OF CONCOMITANT MORBIDITY AND MORTALITY IN DIABETES**  
Farquhar I, Summers KH, Sorkin A, Weir E, ‘The Degge Group, Ltd, Arlington, VA, USA; ‘Eli Lilly & Company, Indianapolis, IN, USA; ‘University of Maryland Baltimore County, Baltimore, MD, USA; ‘Analytical Computing, Baltimore, MD, USA

**INFECTION**

**IN1**  
**META-ANALYSIS OF UTILITY ESTIMATES: HIV/AIDS AND STROKE**  
Tengs TO, Lin TH, Health Priorities Research Group, University of California, Irvine, CA, USA

**IN2**  
**VALUE OF INFORMATION ANALYSIS OF THE DECISION BETWEEN CIPROFLOXACIN VS TRIMETHOPRIM SULPHAMETHOXAZOLE FOR EMPIRICAL TREATMENT OF WOMEN WITH PYELONEPHRITIS**  

**IN3**  
**ECONOMIC EVALUATION OF VACCINATION AGAINST MENINGOCOCCAL DISEASE**  
Milne RJ, Evers J, Ashton T, Lennon D, University of Auckland, Auckland, New Zealand

**IN4**  
**THE COST OF ANTIRETROVIRAL THERAPY IN THREE CENTRAL AMERICAN COUNTRIES**  
Becker R, Zaccagnini P, Rattana S, Ovation Research Group, Highland Park, IL, USA
Concurrent Issues Panels (4 Sessions)

HOW DOES GENOMICS CHANGE PORTFOLIO MANAGEMENT?
Genomics technologies offer substantial promise in the area of clinical development. However, decision-making in an era of a 10-fold increase in targets and limited budgets will require additional discipline and methodologies. We present an options strategy for assessing the potential of new candidate molecules, and then test the concepts with an industry expert.
Chair: Kevin Schulman MD, MBA, Director, Center for Clinical & Genetic Economics, Duke University, Durham, NC, USA

STANDARDS OF EVIDENCE: WHAT IS APPROPRIATE?
This panel will address the question: What should the standards of evidence be for promotional claims by the pharmaceutical and possibly the medical device industries regarding cost effectiveness to assist health care decision-making?
Chair: Bryan Luce PhD, MBA, Senior Research Leader & CEO, MEDTAP International, Bethesda, MD, USA

SHOULD META-ANALYSIS ONLY INCLUDE CLINICAL TRIAL DATA?
This session debates Cochrane collaboration approaches to meta-analysis that excludes all non-RCT data and Bayesian approaches that include uncontrolled trials and observational studies.
Chair: Adrian Towse MA, Mphil, Director, Office of Health Economics, London, United Kingdom

WHO WILL DEVELOP NEW DRUGS FOR TUBERCULOSIS OR MALARIA?
Recent scientific advances offer new promise that breakthrough therapies for the treatment of tuberculosis and malaria could soon be discovered. An increasing focus on global health issues in the public sector and in industry provides a framework for the business case and the partnerships to move these discoveries out of the lab and into the market.
Chair: Doris Rouse PhD, Director, Global Health, RTI International, Research Triangle Park, NC, USA

METHODOLOGY ISSUES

USE AND MISUSE OF DIAGNOSIS RELATED GROUPS (DRGS) IN ESTIMATING COSTS
O’Brien J, Caro Research Institute, Concord, MA, USA

INCIDENCE OR PREVALENCE: IMPLICATIONS FOR FORMULARY DECISION-MAKING
Shaya FT, Mullins CD, Wong W, ‘University of Maryland, Baltimore, MD, USA; ‘CareFirst BlueCross BlueShield, Baltimore, MD, USA

PROBABILISTIC COST-EFFECTIVENESS MODELING: OVERVIEW OF METHODS AND CHALLENGES WITH AN INTERACTIVE ILLUSTRATION

MEASURING PATIENT-REPORTED OUTCOMES IN CANCER STUDIES: PRELIMINARY FINDINGS FROM THE CANCER OUTCOMES MEASUREMENT WORKING GROUP
Lipscomb J, Gotay CC, Snyder C, ‘National Cancer Institute, Bethesda, MD, USA; ‘University of Hawaii, Honolulu, HI, USA

HEALTH POLICY

THE ROLE OF ECONOMIC EVALUATION OF PHARMACEUTICALS IN HEALTH DEVELOPMENT ASSISTANCE
Rovira J, Preker AS, Musgrove PA, The World Bank, Washington, DC, USA

QUALITY OF LIFE

IMPUTATION OF MISSING QOL DATA: METHODS AND INTERPRETATION
Crawford B, Massaro J, ‘Mapi Values, Boston, MA, USA; ‘Boston University, Boston, MA, USA

DESIGN AND IMPLEMENTATION

USING HEALTHCARE CLAIMS DATA TO DEVELOP DISEASE RISK PREDICTION MODELS
Russell MW, Huse DM, ‘ICSL Healthcare Research, Waltham, MA, USA; ‘PharMetrics, Inc, Watertown, MA, USA

COMPARISON OF “TOP-DOWN” VS “BOTTOM-UP” BUDGET IMPACT MODELS
Kleinstiver PW, Katalyst Health Technology Assessments, London, ON, Canada

PRACTICAL ISSUES

INCORPORATING ECONOMIC OUTCOMES INTO FORMULARY DECISIONS
Mauskopf J, Wright A, Hocker S, ‘Research Triangle Institute, RTP, NC, USA; ‘Advance PCS, Hunt Valley, MD, USA; ‘PAREXEL, Baltimore, MD, USA
## Concurrent Contributed Workshop Presentations (9 sessions)

### METHODOLOGY ISSUES

**WW10**  
**NUMBER NEEDED TO TREAT (NNT): IS IT A USEFUL BENCHMARK FOR THE EFFICIENCY OF THERAPIES?**  
Caro J, Huybrechts K, Kamae I, Caro Research Institute, Concord, MA, USA; ‘Kobe University, Chuou-ku, Kobe, Japan

**WW11**  
**THE APPLICATION OF EXPERT OPINION IN PHARMACOECONOMIC STUDIES**  
Evans C, Crawford B, Mapi Values, Boston, MA, USA

**WW12**  
**THE USE OF PATIENT SELF-REPORTED HUMANISTIC OUTCOMES INFORMATION TO IMPROVE QUALITY OF CARE**  
Schmeichel CJ, LeVine P, Netherton D, InfoMedics, Inc, Woburn, MA, USA

**WW13**  
**THE SEER-MEDICARE DATABASE: A UNIQUE RESOURCE FOR PHARMACOECONOMIC RESEARCH IN ONCOLOGY**  
de Lissovoy G, Warren JL, ‘MEDTAP International, Bethesda, MD, USA; ‘National Cancer Institute, Bethesda, MD, USA

### DESIGN AND IMPLEMENTATION

**WW14**  
**INCORPORATING FUTURE EVENTS INTO COST-EFFECTIVENESS MODELS**  
Mauskopf JA, Bala MV, ‘RTI, RTP, NC, USA; ‘Centocor, Inc, Malvern, PA, USA

**WW15**  
**METHODOLOGICAL AND PRACTICAL ISSUES IN DEVELOPING AND ANALYZING ONCOLOGY MODELS**  
Shih YCT, Sorensen S, Nuijten M, ‘MEDTAP International Inc, Bethesda, MD, USA; ‘MEDTAP International, Jisp, Netherlands

**WW16**  
**BENEFITS OF A SIMPLE DECISION ANALYTIC APPROACH TO CLINICAL DRUG DEVELOPMENT**  
Richter A, RTI Health Solutions, Research Triangle Park, NC, USA

**WW17**  
**DECISION ANALYSIS IN THE DRUG DEVELOPMENT PROCESS: USE OF PHARMACOECONOMICS TO INFORM "GO/NO-GO" DECISION MAKING**  
Thompson D, Bird A, Weinstein MC, ‘Innovus Research, Inc, Medford, MA, USA; ‘Harvard School of Public Health, Boston, MA, USA

### PRACTICAL ISSUES

**WW18**  
**EVIDENCE OF THERAPEUTIC EQUIVALENCE: IMPLICATIONS FOR ECONOMIC ANALYSES**  
Ortiz MS, Neighbors DM, Irish W, RTI Health Solutions, Durham, NC, USA

---

### ISPOR Health Science Forum

**Moderator:** John Hutton BSc, Bphil, Chair, ISPOR Health Science Committee & Vice President, European Operations, MEDTAP International, London, UK

ISPOR Health Science Committee Task Force Chairs will provide an update on the “Good Research Practices” initiatives, code of ethics, and use of pharmacoeconomic/health economic information in healthcare decision-making

- Good Modeling Research Practices
- Good Research Practices in Prospective Studies
- Good Research Practices in Retrospective Database Studies
- Good Research Practices in Quality of Life and Performance-based Measurement Studies
- Good Research Practices in the Use of Pharmacoeconomic/Health Economic Information in Healthcare Decision-Making
- Good Research Practices in Code of Ethics

### ISPOR Student Forum

### Exhibitors’ Open House, Poster Presentations – Session I and Reception

---

### TUESDAY, MAY 21, 2002

#### 7:00-8:00  
**Breakfast with the Experts**

- **THEORETICAL ISSUES IN COST-EFFECTIVENESS ANALYSIS**  
  Milton Weinstein PhD, Professor, Health Policy & Management, Center for Risk Analysis, Harvard School of Public Health, Boston, MA, USA

- **NICE**  
  Andrew H. Briggs DPhil, Health Economics Research Centre, Institute of Health Sciences, Oxford University, Oxford, United Kingdom

- **QUALITY OF LIFE RESEARCH**  
  Pennifer Erickson PhD, Co-founder, O.L.G.A, State College, PA, USA

- **OUTCOMES RESEARCH IN THE PHARMACEUTICAL INDUSTRY**  
  Marc Berger MD, Vice President, Outcomes Research & Management, Merck & Company, Inc., West Point, PA, USA
**Concurrent Podium Sessions (4 sessions)**

Study results and issues on the following topics will be discussed.

### METHODOLOGY ISSUES I

<table>
<thead>
<tr>
<th>MI1</th>
<th>HANDLING MISSING DATA IN STOCHASTIC COST-EFFECTIVENESS ANALYSIS: THE IMPACT OF IMPUTATION METHODS ON ESTIMATES OF THE PHYSICAL QUANTITIES OF MEDICAL CARE RESOURCE USE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bell TJ</td>
<td>Liu J, Backhouse M, Research Triangle Institute, Raleigh-Durham, NC, USA; ‘Research Triangle Institute, Manchester, UK</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MI2</th>
<th>COST-EFFECTIVENESS VS. COST-UTILITY ANALYSIS: DOES ADJUSTING FOR HEALTH-RELATED QUALITY OF LIFE REALLY MATTER?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tenos TO</td>
<td>Lin TH, Health Priorities Research Group, University of California, Irvine, CA, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MI3</th>
<th>IMPORTANCE OF CONSIDERING SENSITIVITY AND SPECIFICITY OF SCREENING METHODS IN HEALTH ECONOMIC ANALYSES OF DIABETIC NEPHROPATHY SCREENING POLICIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palmer AJ</td>
<td>Roze S, CORE Center for Outcomes Research, Basel, BS, Switzerland</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MI4</th>
<th>THE DANGER OF IGNORING POPULATION HETEROGENEITY WHEN MARKOV MODELS ARE USED FOR COST EFFECTIVENESS ANALYSIS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zaric GS</td>
<td>University of Western Ontario, London, ON, Canada</td>
</tr>
</tbody>
</table>

### HEALTH POLICY – COMPLIANCE ISSUES

<table>
<thead>
<tr>
<th>HP1</th>
<th>SUB-OPTIMAL STATIN COMPLIANCE IN PRIMARY AND SECONDARY PREVENTION POPULATIONS: SHOULD WE TARGET PATIENTS WITH THE MOST TO GAIN?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ellis JJ</td>
<td>Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM, ‘University of Michigan, Ann Arbor, MI, USA; ‘Veterans Affairs Medical Center, Ann Arbor, MI, USA; ‘Vanderbilt University, Nashville, TN, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HP2</th>
<th>IS IT COST-EFFECTIVE TO IMPROVE COMPLIANCE WITH LIPID-LOWERING THERAPY?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benner JS</td>
<td>Ganz DA, Weinstein MC, Neumann PJ, Glynn RJ, Avorn J, ‘Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, USA; ‘Harvard School of Public Health, Boston, MA, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HP3</th>
<th>IMPROVING THE SAFETY OF AMIODARONE IN THE CONGESTIVE HEART FAILURE POPULATION: BASELINE ASSESSMENT OF COMPLIANCE WITH NATIONAL GUIDELINES IN A LARGE CHF CLINIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Just VL</td>
<td>Williams RE, Evanston Northwestern Healthcare, Evanston, IL, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HP4</th>
<th>THE IMPACT OF ADHERENCE TO OSTEOPOROSIS THERAPY ON FRACTURE RATES IN ACTUAL PRACTICE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caro J</td>
<td>Huybrechts K, Ishak K, Naujoks C, ‘Caro Research Institute, Concord, MA, USA; ‘Caro Research Institute, Dorval, QC, Canada; ‘Novartis Pharma AG, Basel, Switzerland</td>
</tr>
</tbody>
</table>

### CARDIOVASCULAR DISEASE/DISORDERS II

<table>
<thead>
<tr>
<th>CV5</th>
<th>COST-EFFECTIVENESS OF STATINS IN PRIMARY PREVENTION OF CHD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wendl G</td>
<td>Lauterbach K, ‘Cologne, NW, Germany; ‘University of Cologne, Cologne, Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CV6</th>
<th>COMPARING RECENT CARDIOVASCULAR MEDICATIONS USING AN NNT MODEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caro J</td>
<td>Ishak K, Caro I, Migliaccio-Walle K, ‘Caro Research Institute, Concord, MA, USA; ‘Caro Research Institute, Dorval, QC, Canada</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CV7</th>
<th>COST-EFFECTIVENESS OF ADENOSINE AND DIPYRIDAMOLE IN TECHNETIUM-99M SESTAMIBI SINGLE PHOTON COMPUTED TOMOGRAPHY IMAGING</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>CV8</th>
<th>FORMULARY DECISIONS: THE USE OF MULT-ATTRIBUTE ANALYSIS – A BASELINE CASE STUDY OF PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hess GP</td>
<td>Kroch F, Yaffe K, Barbaccia JG, ‘Wayne, PA, USA; ‘CareScience, Philadelphia, PA, USA; ‘Norristown, PA, USA; ‘Washington Hospital Center, Washington, DC, USA</td>
</tr>
</tbody>
</table>

### CANCER

<table>
<thead>
<tr>
<th>CN1</th>
<th>ECONOMIC EVALUATION OF CAPECITABINE-DOCETAXEL COMBINATION TREATMENT OF METASTATIC BREAST CANCER: A MICRO-SIMULATION STUDY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hornberger J</td>
<td>Jamieson C, ‘Acumen, LLC and Stanford University School of Medicine, Burlingame, CA, USA; ‘Roche Pharmaceuticals, Palo Alto, CA, USA; ‘US Oncology-Baylor-Sammons Cancer Center, Dallas, TX, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CN2</th>
<th>COST-UTILITY ANALYSIS OF LHRR AGONISTS IN THE TREATMENT OF METASTATIC PROSTATE CANCER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemels M</td>
<td>Iskedjian M, Iscoe N, Fleschner N, Einason T, ‘University of Toronto, Toronto, ON, Canada; ‘Pharmidea Research and Consulting Inc, Oakville, ON, Canada; ‘Toronto-Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; ‘Sunnybrook and Women’s Health Sciences Center, Toronto, ON, Canada</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CN3</th>
<th>BEHIND THE VEIL OF IGNORANCE: ASSESSMENT OF PREFERENCES AND UTILITIES FROM MEN AT-RISK FOR PROSTATE CANCER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bruner DW</td>
<td>Hanlon A, Sargent T, Mazzoni S, Raynor S, Hanks G, ‘Fox Chase Cancer Center, Cheltenham, PA, USA; ‘formerly from Fox Chase Cancer Center, Philadelphia, PA, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CN4</th>
<th>COMPARISON OF TREATMENT MODALITIES IN PROSTATE CANCER PATIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morris L</td>
<td>Margolis J, Henderson SC, von Allmen H, IMS HEALTH, Plymouth Meeting, PA, USA</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>-------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>9:30-10:00</td>
<td>Exhibits &amp; Poster Presentations – Session II</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Incoming Presidential Address</td>
</tr>
<tr>
<td></td>
<td><strong>Peter Davey MD, FRCP</strong>, 2002-2003 ISPOR President &amp; Head of Pharmacoeconomics, University of Dundee, Dundee, Scotland, UK</td>
</tr>
<tr>
<td></td>
<td><strong>Presentations: ISPOR Research Excellence Awards</strong></td>
</tr>
<tr>
<td>10:30-12:00</td>
<td>Second Plenary Session</td>
</tr>
<tr>
<td></td>
<td><strong>&quot;THE RISE OF RISK MANAGEMENT&quot;</strong></td>
</tr>
<tr>
<td></td>
<td>Recent trends in the withdrawal of drugs from the market highlight a new era of risk control. The Food and Drug Administration (FDA) has publicly exclaimed that traditional means of assuring safe use (e.g. product labels, dear health professional letters) may not be sufficient to assure continued marketing of pharmaceutical products. Rather, new risk management techniques may be necessary to assure that drugs are used safely and effectively. This session will discuss the FDA's new philosophy of risk management as a public health priority. It will also discuss alternative models for examining risk management from an economic/public policy perspective. In addition, this session will discuss an evolving role for outcomes researchers in the development and evaluation of risk management mechanisms.</td>
</tr>
<tr>
<td></td>
<td><strong>Moderator:</strong> Peter Neumann ScD, ISPOR Annual Meeting Program Chair and Assistant Professor of Policy &amp; Decision Sciences, Harvard School of Public Health, Boston, MA, USA</td>
</tr>
<tr>
<td></td>
<td><strong>Speaker:</strong> John D. Graham PhD, Administrator, Office of Management and Budget, Washington, DC, USA</td>
</tr>
<tr>
<td></td>
<td><strong>Speaker:</strong> Janet Woodcock MD, Director for Drug Evaluation &amp; Research, Rockville, MD, USA</td>
</tr>
<tr>
<td>12:00-1:30</td>
<td>Exhibits, Poster Presentations – Session II and Lunch</td>
</tr>
<tr>
<td>1:30-2:30</td>
<td>Concurrent Issues Panels (4 Sessions)</td>
</tr>
<tr>
<td></td>
<td><strong>IS $50,000/QALY HIGH ENOUGH FOR A US BENCHMARK?</strong></td>
</tr>
<tr>
<td></td>
<td>Panel will debate the appropriateness of the use of quality adjusted life years (QALYs) as common benefit measure of medical interventions. The implications of setting a specific threshold level and whether the oft-quoted $50,000/QALY threshold is a feasible benchmark for the US will be discussed.</td>
</tr>
<tr>
<td></td>
<td><strong>Chair:</strong> A. Mark Fendrick MD, Associate Professor, University of Michigan Medical Center, Ann Arbor, MI, USA</td>
</tr>
<tr>
<td></td>
<td><strong>WHAT’S NEXT FOR OUTCOMES RESEARCH IN ASIA?</strong></td>
</tr>
<tr>
<td></td>
<td>This session will identify and discuss key issues of conducting pharmacoeconomics and health outcomes research in Asia. Also, the roles of different players (government, academic, industry, etc) will be discussed.</td>
</tr>
<tr>
<td></td>
<td><strong>Chair:</strong> Hong Li PhD, Associate Director, Bristol-Myers Squibb, Wallingford, CT, USA</td>
</tr>
<tr>
<td></td>
<td><strong>MEDICATION COMPLIANCE: HOW CAN IT BE INCLUDED IN PHARMACOECONOMIC STUDIES?</strong></td>
</tr>
<tr>
<td></td>
<td>Panelists will discuss compliance in the context of modeling clinical and economic outcomes of care.</td>
</tr>
<tr>
<td></td>
<td><strong>Chair:</strong> Joyce Cramer BS, Associate Research Scientist, Yale University School of Medicine, West Haven, CT, USA</td>
</tr>
<tr>
<td></td>
<td><strong>USING HEALTH ECONOMIC AND OTHER OUTCOMES INFORMATION TO DEVELOP SOUND PRESCRIPTION DRUG PLANS: PRACTICAL OR IMPOSSIBLE IN THE US?</strong></td>
</tr>
<tr>
<td></td>
<td>Managed care and others are looking to pharmacoeconomic and outcomes research in developing drug plans. Will different, more informed decisions result? What are the obstacles?</td>
</tr>
<tr>
<td></td>
<td><strong>Chair:</strong> Joanna Siegel ScD, Director, Research Initiative in Clinical Economics, Agency for Healthcare Research &amp; Quality, Rockville, MD, USA</td>
</tr>
<tr>
<td>2:30-2:45</td>
<td>Break</td>
</tr>
</tbody>
</table>
2:45-3:45 Concurrent Contributed Workshop Presentations (8 sessions in 4 categories)

**METHODOLOGY ISSUES**

**WW19 METHODOLOGICAL ISSUES IN MEASURING AND INFLUENCING ANTIBIOTIC PRESCRIBING IN HOSPITALS**
Davey PG, Ofori BD, 'University of Dundee, Dundee, United Kingdom; 'Ninewells Hospital and Medical School, Dundee, United Kingdom

**WW20 METHODOLOGICAL CHALLENGES IN RETROSPECTIVE DATABASE STUDIES: STEPS FOR GETTING IT RIGHT**
Menzin J, Langa K, Boston Health Economics, Waltham, MA, USA

**WW21 ISSUES IN THE SPECIFICATION OF PERFORMANCE MEASURES: INSIGHTS FROM THE STUDY OF CLINICALLY RELEVANT INDICATORS OF PHARMACOLOGIC THERAPY (THE SCRIPT PROJECT)**
Edward W, Kogut S, Massachusetts Peer Review Organization, Inc, Waltham, MA, USA

**WW22 PSYCHOMETRICS FOR THE NON-PSYCHOMETRICIAN**
Fehnel SE, McLeod LD, RTI Health Solutions, Research Triangle Park, NC, USA

**HEALTH POLICY**

**WW23 PAVING A ROAD TO SUCCESS: HOW TO OBTAIN AN OUTCOMES RESEARCH FELLOWSHIP WITHIN THE PHARMACEUTICAL INDUSTRY**
Carter CT, Maio V, Pizzi L, Lofland J, Thomas Jefferson University, Philadelphia, PA, USA

**WW24 RISE OF CONSUMERISM – UNDERSTANDING CONSUMER SOVEREIGNTY**
Heissel A, Ethicon Endo-Surgery (Europe) GmbH, Norderstedt, Germany

**DESIGN AND IMPLEMENTATION**

**WW25 MEASURING VALUE IN THE DRUG DEVELOPMENT PROCESS: HOW DO YOU KNOW IT IS THERE?**
Paul JE, Backhouse ME, 'RTI Health Solutions, Research Triangle Park, NC, USA; 'RTI Health Solutions, Manchester, United Kingdom

**WW26 MAXIMIZING THE SCIENTIFIC AND STRATEGIC VALUE OF PATIENT REGISTRIES**
Trotter J, Larson L, Vreeland MG, Ovation Research Group, Highland Park, IL, USA

**PRACTICAL ISSUES**

**WW27 EVALUATION OF HEALTH ECONOMIC INFORMATION USED IN PROMOTION**
Piault E, Cronin K, Mathieu J, Hu EJ, Burke LB, Food and Drug Administration, Rockville, MD, USA

3:45-4:00 Break

4:00-5:30 Medical Device & Diagnostics Forum

"USING MEDICAL DEVICE AND DIAGNOSTICS OUTCOMES RESEARCH TO SUPPORT HEALTH POLICY & REIMBURSEMENT DECISIONS"
This Forum is coordinated by the ISPOR Medical Device and Diagnostics Council (http://www.ispor.org/committees/advcouncils.asp)

4:00 - 4:30pm USING OUTCOMES RESEARCH STUDIES TO SUPPORT IMPROVED PRODUCTIVITY
Private payers are using HEDIS measurements to imply greater productivity to employers. This presentation will focus on how outcomes research studies can be used to support improved workplace productivity.

**Speaker:** Sean Sullivan, Institute for Health and Productivity Management, Scottsdale, AZ, USA

4:30 - 5:00pm HOW TO SUPPORT REIMBURSEMENT OF OFF-LABEL USE OF MEDICAL DEVICES AND DIAGNOSTICS: WILL OUTCOMES RESEARCH HELP?
During the diffusion of innovation process, new medical technologies are used to treat or reduce symptoms in ways other than described on the labeling. This presentation will focus on off-label use of medical and diagnostic technologies, associated reimbursement issues, as well as research opportunities to support reimbursement decisions.

**Speaker:** TBD

5:00 - 5:30pm QUESTIONS AND AUDIENCE PARTICIPATION

4:00-5:30 Quality of Life Forum

"SUMMARY MEASURES OF POPULATION HEALTH STATUS – WHO CARES?"
This Forum is coordinated by the ISPOR Quality of Life Special Interest Group (http://www.ispor.org/sigs/sigsindex.asp)

Measuring health outcomes is a key component in establishing the cost-effectiveness of any new therapy as well as the measurement of population health. The World Health Organization (WHO) has setup new programmes to describe and value health/health-related quality of life (HRQOL) for the evaluation of healthcare. This work has serious implications for government health agencies, the pharmaceutical industry and the wider research community. Can there ever be a single common means of describing health/HRQOL? How portable are concepts of health between countries? How are they influenced by factors such as age, gender, education or ethnicity? Whose values should count and do values transcend countries? Is it meaningful to consider a single "world" value set? If our governments listen to WHO on this agenda, ISPOR members should be sufficiently well informed to be able to have their say too.

**Moderator:** Joyce Cramer, Associate Research Scientist, Yale University School of Medicine, New Haven, CT, USA
4:00 – 4:20pm  THE WHO MEASUREMENT OF POPULATION HEALTH INITIATIVE  
**Speaker:** Mark Miller PhD, Director, Division of International Epidemiology and Populations Studies, Fogarty International Center, National Institute of Health, Bethesda, MD USA

4:20 - 4:40pm  MEASURING HEALTH STATUS IN NATIONAL POPULATION SURVEYS: US EXPERIENCE AND ISSUES RELEVANT TO THE WHO INITIATIVE  
**Speaker:** Edward Sondik PhD, Director, National Center for Health Statistics, Center for Disease Control, Hyattsville, MD, USA

4:40 – 5:00pm  USING POPULATION HEALTH STATUS MEASURES IN CLINICAL STUDIES: INFORMATIONAL AND INTERNATIONAL IMPLICATIONS  
**Speakers:** Pennifer Erickson PhD, Co-founder, O.L.G.A, State College, PA, USA and Diane Wild MSc, Partner, Oxford Outcomes, Headington, Oxford, UK

5:00 –5:20pm  PANEL AND AUDIENCE DISCUSSION

5:20 – 5:30pm  RAPPORTEUR  
**Presenter:** Paul Kind Mphil, Senior Research Fellow, Outcomes Research Group, Centre for Health Economics, University of York, York, UK

5:30 – 6:00 ISPOR Quality of Life Special Interest Group Meetings (followed by reception)

5:30 – 6:00 ISPOR Business Meeting (followed by reception)

### WEDNESDAY, MAY 22, 2002

7:00-8:00  Breakfast with the Experts  
**COST-EFFECTIVENESS ANALYSIS IN THE DEVELOPING WORLD**  
Joan Rovira PhD, Health, Nutrition and Population, The World Bank, Washington, DC, USA

**ISSUES IN MODELING IN COST-EFFECTIVENESS**  
J. Jaime Caro MD, Scientific Director, Caro Research, Concord, MA, USA

**ECONOMIC EVALUATION ALONGSIDE CLINICAL TRIALS**  
Henry Glick PhD, Health Economist, Division of Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA

**PHARMACEUTICAL COSTS, EXPENDITURES AND POLICY IMPLICATIONS**  
C. Daniel Mullins PhD, Associate Professor, University of Maryland, School of Pharmacy, Baltimore, MD, USA

8:30-10:00  Concurrent Podium Sessions (4 Sessions)  
Pharmacoeconomic/health economic, quality-of-life and outcomes research study results for the following diseases will be presented.

### METHODOLOGY ISSUES II

**M15**  
**EXPLORING THE DERIVATION OF UTILITY VALUES USING A DISCRETE-CHOICE CONJOINT ANALYSIS METHOD – A COST-UTILITY ANALYSIS OF GEMCITABINE PLUS CISPLATIN FOR THE TREATMENT OF BLADDER CANCER**  
Davey P1, Rajan N2, 1M-TAG, Sydney, NSW, Australia; 2Eli Lilly Australia Pty Ltd, Sydney, NSW, Australia

**M16**  
**ARE THE FRAMINGHAM-RISK EQUATIONS VALID FOR EUROPE?**  
Wendland G1, Lauterbach K2, 1Cologne, NW, Germany; 2University of Cologne, Cologne, Germany

**M17**  
**HOSPITAL-SPECIFIC RELATIVE INTENSITY SCORES FOR PHARMACEUTICAL SERVICES**  
Foster DA1, Solucient, LLC, Ann Arbor, MI, USA

**M18**  
**DEVELOPING A QUALITY APPRAISAL INSTRUMENT TO EVALUATE THE PEDIATRIC HEALTH ECONOMICS LITERATURE**  
Ungar WJ1, Menon D2, Lee A3, Stafinski T1, 1The Hospital for Sick Children Research Institute, Toronto, ON, Canada; 2Institute of Health Economics, Edmonton, AB, Canada

### HEALTH POLICY – CONSUMER ADVERTISING ISSUES

**H5**  
**THE RELATIONSHIP OF DIRECT-TO-CONSUMER ADVERTISING AND CLINICIAN BEHAVIORAL INTENTIONS**  
Zachry III WM, Jackson TR, The University of Arizona, Tucson, AZ, USA

**H6**  
**RELATIONSHIP OF DIRECT-TO-CONSUMER ADVERTISING SPENDING AND DRUG PRICING FOR THE TOP TWENTY DRUGS FROM 1997 TO 2000: AN EXPLORATORY STUDY**  
Parthan AG1, Anantharaman RT2, Shepherd MD3, The University of Texas at Austin, Austin, TX, USA

**H7**  
**IMPACT OF DIRECT TO CONSUMER ADVERTISING - THE CONSUMER SEARCH FOR INFORMATION**  
Belazi DT1, Crawford A2, Pizzi L3, 1Thomas Jefferson University & Abbott Laboratories, Philadelphia, PA, USA; 2Thomas Jefferson University, Philadelphia, PA, USA

**H8**  
**FDA REGULATORY ACTIONS AGAINST MISLEADING OR UNSUBSTANTIATED ECONOMIC AND QUALITY-OF-LIFE CLAIMS: AN ANALYSIS OF WARNING LETTERS AND NOTICES OF VIOLATION**  
Stewart KA1, Neumann PJ2, Harvard School of Public Health, Boston, MA, USA
### ASTHMA & RESPIRATORY DISORDERS/INFECTIONS

<table>
<thead>
<tr>
<th>Paper</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>AR1</td>
<td>RELATIONSHIP BETWEEN DIFFERENT MEASURES OF ASTHMA SEVERITY: PATIENT-PERCEIVED, SYMPTOM DERIVED, AND FEV1 DETERMINED SEVERITY MEASURES</td>
<td>Erickson SR, Kirking DM, Bria WF</td>
<td>University of Michigan, Ann Arbor, MI, USA</td>
</tr>
<tr>
<td>AR2</td>
<td>DIRECTLY ELICITED PREFERENCES COMPARED TO PREFERENCES DERIVED FROM THE SF-36 IN ADULT ASTHMATICS</td>
<td>Lee TA, Hollingworth W, Sullivan SD</td>
<td>Hines VA Hospital, Hines, IL, USA; University of Cambridge, Cambridge, UK; University of Washington, Seattle, WA, USA</td>
</tr>
<tr>
<td>AR3</td>
<td>MOXIFLOXACIN IV/PO MONOTHERAPY IS COST-EFFECTIVE TO THE GERMAN AND FRENCH HEALTHCARE SYSTEMS WHEN COMPARED TO IV/PO AMOXICILLIN/CLAVULANATE ± CLARITHROMYCIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA</td>
<td>Drummond M, Becker D, Hux M, Chancellor J, Duprat-Lomon I, Sagnier P</td>
<td>Innovus Research (UK) Ltd. and University of York, Heslington, York, UK; Innovus Research Inc, Burlington, ON, Canada; Innovus Research (UK) Ltd, Amersham, Buckinghamshire, UK; Bayer Pharma, Puteaux, France; Bayer plc, Slough, UK</td>
</tr>
<tr>
<td>AR4</td>
<td>PSYCHOMETRIC PROPERTIES OF THE ACUTE BRONCHITIS SYMPTOM SEVERITY SCALE IN AN INTERNATIONAL SAMPLE</td>
<td>Margolis MK, Frank L, Leidy NK, Duprat-Lomon I, Amiot N, Sagnier PP</td>
<td>MEDTAP International, Bethesda, MD, USA; Bayer Pharma, Puteaux, France; Bayer plc, Slough, UK</td>
</tr>
</tbody>
</table>

### NEUROLOGICAL/PAIN DISORDERS

<table>
<thead>
<tr>
<th>Paper</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>NP1</td>
<td>INDIRECT COSTS DUE TO BACK PAIN IN THE UNITED STATES</td>
<td>Mychaskiw MA, Thomas III J</td>
<td>Purdue University, West Lafayette, IN, USA</td>
</tr>
<tr>
<td>NP2</td>
<td>EXCESSIVE COSTS RESULTING FROM PRIMARY CARE AND CHIROPRACTIC UTILIZATION OF DIAGNOSTIC IMAGING IN THE FIRST WEEK OF CARE FOR ACUTE LOW BACK PAIN</td>
<td>Jackson SL, Kim S, Seifelden R, Papatheofanis F</td>
<td>Aequitas Consulting Group, San Diego, CA, USA; Purdue Pharma, Stamford, CT, USA; University of California San Diego, La Jolla, CA, USA</td>
</tr>
<tr>
<td>NP3</td>
<td>AN ITEM ANALYSIS OF THE 24 HOUR HEADACHE DISABILITY QUESTIONNAIRE (DISQ-24) USING CLASSICAL TEST THEORY AND ITEM RESPONSE THEORY METHODS</td>
<td>Ayyar Krishnan A, Kwong WJ</td>
<td>University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; GlaxoSmithKline, Research Triangle Park, NC, USA</td>
</tr>
<tr>
<td>NP4</td>
<td>TOTAL HEALTHCARE EXPENDITURES FOR MIGRAINE PATIENTS ASSOCIATED WITH CHOICE OF DRUG THERAPY</td>
<td>Schabert VF, Esposito D, Bowers BW, Rousey A, Tillotson F</td>
<td>The MEDSTAT Group, Santa Barbara, CA, USA; GlaxoSmithKline, Research Triangle Park, NC, USA</td>
</tr>
</tbody>
</table>

#### 10:00-10:30 Break

#### 10:30-12:00 Presentation: ISPOR Contributed Research Paper Awards

**Third Plenary Session**

"THE RISE OF CONSUMERISM"

The evolution of managed care has given rise to the consumer as the most powerful entity in the setting of coverage priorities. With increased emphasis on direct-to-consumer (DTC) promotion and the Internet’s disintermediation, consumers have become more knowledgeable and more opinionated about the treatments they want covered. This session will discuss how managed care is changing to accommodate the consumer’s interests, what consumers want from managed care and opportunities for outcomes researchers to understand consumer needs, provide consumers with information that can help them make wise decisions, and to evaluate the impact of consumer preferences and decision-making on the outcomes of care.

**Moderator:** Louis A. Morris PhD, ISPOR Annual Meeting Plenary Session Chair and President, Louis A. Morris & Associates, Dix Hills, NY, USA

**Speaker:** Linda F. Goldner, Executive Director, National Consumer League, Washington, DC, USA

**Speaker:** Karen Donelan ScD, Senior Vice President, Medrock, Cambridge, MA, USA

**Discussant:** Newell McElwee PharmD, MSPH, Senior Director/Team Leader, Global Outcomes Research, Pfizer, Inc, New York, NY, USA

**Discussant:** TBD

#### 12:00 Adjournment
HEALTH POLICY

Health Outcomes Presentations

PHP1 AN ANALYSIS OF A HEALTHY START SMOKING CESSATION PROGRAM
Mayhew DY, Perrin KM, Struchen W, ’University of Florida, Gainesville, FL, USA; ’University of South Florida, Tampa, FL, USA; 1Florida Department of Health, St. Petersburg, FL, USA

PHP2 THE EFFECT OF PREFERRED DRUG STATUS ON PATIENT SWITCHING, ADHERENCE, AND DAYS OF THERAPY
Hutchison S, Miller T, AdvancePCS, Scottsdale, AZ, USA

PHP3 ASSESSING FRACTURE RISK WITH PRESCRIPTION DRUGS IN MEDICARE-ELIGIBLE PLAN MEMBERS OF A TELECOMMUNICATIONS COMPANY
Erwin G, Kleinman N, Astuto J, Gardner H, Lipson L, Stuart B, Wilson P, ’Omnicare, King of Prussia, PA, USA; ’Options & Choices, Inc, Cheyenne, WY, USA; ’Verizon Communications, Alpharetta, GA, USA; ’University of Southern California School of Medicine, Los Angeles, CA, USA; ’University of Maryland, Baltimore, MD, USA; 1Associates & Wilson, Rosemont, PA, USA

PHP4 GENERIC NARROW THERAPEUTIC INDEX DRUG USE: 1996-1998
Chao J, Taylor SD, McKercher PL, Kirking DM, University of Michigan, Ann Arbor, MI, USA

PHP5 IMPACT OF MULTI-TIERED PHARMACY BENEFITS ON MEDICATION ADHERENCE
Valuck RJ, Nair K, Wolfe P, McCollum M, Lewis S, ’University of Colorado School of Pharmacy, Denver, CO, USA; ’Wolfe Statistical Consulting, LLC, Denver, CO, USA; ’Anthem Blue Cross Blue Shield of Colorado, Denver, CO, USA

PHP6 AN ANALYSIS OF THE EFFECT OF MANAGED CARE IMPLEMENTATION ON PRESCRIPTION DRUG UTILIZATION BY TEXAS MEDICAID CLIENTS
Richards KM, University of Texas, Austin, TX, USA

PHP7 HORIZONTAL INEQUITY IN HEALTH CARE UTILIZATION IN JAPAN
Honda C, Ohkusa Y, ’Yao Health Center, Osaka Prefecture, Ibaragi, Osaka, Japan; ’Osaka University, Ibaragi, Osaka, Japan

PHP8 PERCEPTIONS OF COUNSELING FOR OBESITY AND RELATED BARRIERS AMONG COMMUNITY PHARMACISTS IN TEXAS
Dastani HB, Brown CM, University of Texas at Austin, Austin, TX, USA

PHP9 STRATEGIES TO REDUCE PREVENTABLE DRUG-RELATED MORBIDITY
Flanagan PS, MacKinnon NJ, Hanlon NT, Robertson HA, ’Dalhousie University, Halifax, Nova Scotia, Canada; ’University of Northern British Columbia, Prince George, British Columbia, Canada

PHP10 USE OF HEALTH OUTCOMES DATA IN PROMOTIONAL MATERIALS
Harris SD, Bryant-Comstock L, ’GlaxoSmithKline, Global Health Outcomes Dept, RTP, NC & University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ’GlaxoSmithKline, Global Health Outcomes Dept, Research Triangle Park, NC, USA

PHP11 A DESCRIPTION OF DISCARDED PRESCRIPTION DRUGS
Tennyson DH, Auburn University, Auburn, AL, USA

PHP12 CHANGING DRUG SELLER BEHAVIOR ON CHILD DIARRHEA MANAGEMENT: EFFECTIVENESS OF TRAINING PROGRAM AND IMPLICATIONS OF KNOWLEDGE-PRACTICE GAP
Ratanawijitrasin S, Panyawuthikrai P, Suttajit S, Hongsamoot D, ’Chulalongkorn University, Bangkok, Thailand; ’Food and Drug Administration, Nonthaburi, Thailand

PHP13 THE ROLE OF VARIOUS FACTORS IN THE DRUG FORMULARY DECISION-MAKING PROCESS
MacKinnon NJ, Kumar R, Chaudhry DAN, Dalhousie University, Halifax, NS, Canada

PHP14 IMPACT OF MULTI-TIERED PHARMACY BENEFITS ON PATIENT ATTITUDES AND BEHAVIOR
Nair KV, Wolfe P, Ganther JM, Valuck RV, McCollum M, Lewis SJ, ’University of Colorado Health Sciences Center, School of Pharmacy, Denver, CO, USA; ’Wolfe Statistical Consulting, LLC, Denver, CO, USA; ’University of Iowa, Iowa City, IA, USA; ’Anthem Blue Cross Blue Shield of Colorado, Denver, CO, USA

PHP15 SURVIVAL RATES FOR PATIENTS RECEIVING TRANSFUSIONS IN THE UNITED STATES FROM AN ADMINISTRATIVE MANAGED CARE DATABASE
Grima D, Marshall D, Kleinman S, AuBuchon J, Kulin N, Cheng R, ’Innovus Research Inc, Burlington, ON, Canada; ’Kleinman Biomedical Research, Victoria, BC, Canada; ’Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA; ’Protocare Sciences Inc, Santa Monica, CA, USA

PHP16 PATIENT SATISFACTION AND PHARMACEUTICAL OUTPATIENT CARE
Huttin CC, University of Paris, Paris, France and ElASM, Brussels, Belgium

PHP17 DRUG INSURANCE TYPE AND INAPPROPRIATE PRESCRIPTIONS FOR THE ELDERLY: ANY CONNECTIONS?
Liu GG, Fu AZ, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

PHP18 STOP: SMOKING CESATION TARGET: OBSERVATORY PROGRAM, THE FRENCH PHYSICIAN’S PROGRESS
Taieb C, Myon E, PharmacoEconomics Programs, bioMérieux-Pierre Fabre, Boulogne Billancourt, France

PHP19 MEDICATION SUPPORT PROGRAM IMPROVES MEDICATION COMPLIANCE
Taitel MS, Frick J, Herman P, Kurcz L, Smith S, First Health, Downers Grove, IL, USA

PHP20 SURVIVAL ANALYSIS IN SEDATED INTENSIVE CARE UNIT (ICU) PATIENTS
Chakledkaew U, Hopeff AW, Kamath TV, Johnson KA, ’University of Southern California, Los Angeles, CA, USA; ’AmeriNet, St. Louis, MO, USA; ’Bristol-Myers Squibb Company, Princeton, NJ, USA

PHP21 THERAPEUTIC INTERCHANGEABILITY OF LEVOTHYROXINE
von Scheele B, Sherrill B, Giliesen AW, Richter A, Devlin P, RTI Health Solutions, Research Triangle Park, NC, USA

Economic Outcomes Presentations

PHP22 USING THE AMERICAN PRODUCTIVITY AUDIT (APA) TO INFORM EMPLOYERS ABOUT THE WORK-RELATED COST OF HEALTH CONDITIONS IN THEIR WORKFORCE
Matousek DM, Ricci J, Stewart W, Chee E, AdvancePCS, Center for Work & Health, Hunt Valley, MD, USA

PHP23 PREVENTABLE DRUG-RELATED MORBIDITY AND MORTALITY IN OLDER ADULTS: A CANADIAN COST-OF-ILLNESS MODEL
Kidney T, MacKinnon NJ, Dalhousie University, Halifax, NS, Canada
Quality of Life Presentations

**PHP49** QALYS FROM PREVENTING SMOKING, ENCOURAGING CESSION, OR AVERTING RELAPSE: RESULTS FROM THE TOBACCO POLICY MODEL

Tenos TD, Osgood ND, Lin TH, Health Priorities Research Group, University of California, Irvine, CA, USA

**PHP50** HEALTH-RELATED QUALITY OF LIFE IN HEMOPHILIA AND VON WILLEBRAND'S DISEASE: MEASUREMENT PROPERTIES OF THE HEALTH UTILITIES INDEX

Horsman JR, Furlong W, Barr RD, Sek J, Pai M, Walker I, McMaster University, Hamilton, ON, Canada

**PHP51** IMPROVED QUALITY OF LIFE AND DECREASED USE OF HEALTHCARE RESOURCES ARE MAINTAINED DURING 3 YEARS OF GROWTH HORMONE (GH) SUBSTITUTION IN HYPOPITUITARY ADULTS WITH GH DEFICIENCY


**PHP52** A RANDOMIZED, OPEN-LABEL PREFERENCE STUDY OF GENGRAF® COMPARED TO NEORAL® IN STABLE ORGAN TRANSPLANT RECIPIENTS

Steinberg S, Venuto R, Kuruvilla KC, Taylor D, Anil Kumar MS, First MR, Greco R, Bodhoo TI, Singh A, Ashraf T, Japour AJ, Ryan J, Balboa Nephrology Medical Group, San Diego, CA, USA; Erie County Medical Center, Buffalo, NY, USA; South Denver Nephrology Associates, Denver, CO, USA; Cleveland Clinic Foundation, Cleveland, OH, USA; Hahnmann University Hospital, Philadelphia, PA, USA; University Hospital, Cincinnati, OH, USA; Abbott Laboratories, Abbott Park, IL, USA

**PHP53** STUDY OF SF-36V2 IN A MONTANA NATIVE AMERICAN POPULATION

Carter JT, The University of Montana, Missoula, MT, USA

**PHP54** PREVENTABLE DRUG-RELATED MORBIDITY IN OLDER ADULTS IN NOVA SCOTIA, CANADA: DEVELOPMENT OF QUALITY INDICATORS

Robertson H, MacKinnon NJ, Tonks RS, Dalhouise University, Halifax, NS, Canada

**PHP55** CONTENT ANALYSIS OF QUALITY OF LIFE AND PHARMACOECONOMIC MESSAGES IN PHARMACEUTICAL PRODUCT ADVERTISEMENTS

Munch EA, Stolshke B, Grizzle AJ, University of Arizona College of Pharmacy, Tucson, AZ, USA; Amgen, Inc, Thousand Oaks, CA, USA

Economic Outcomes Presentations

**PCV11** THE COST OF WARFARIN MONITORING IN ANTICOAGULATION CLINICS: A MULTI-SITE MANAGED CARE STUDY

Menzin J, Boulanger L, Hauch O, Friedman M, Marple C, Wygant G, Hurley J, Pezzella S, Kaatz S, Boston Health Economics, Waltham, MA, USA; AstraZeneca, L.P, Wayne, PA, USA; LifeLine Respiratory Research Institute, Albuquerque, NM, USA; Fallon Clinic, West Boylston, MA, USA; Henry Ford Clinic, Detroit, MI, USA

**PCV12** IMPACT OF ATRIAL FIBRILLATION ON RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH UNDERLYING CARDIOVASCULAR DISEASES

Doshi JA, Khandker RK, Roth DA, University of Maryland, Baltimore, MD, USA; GlaxoSmithKline, Collegeville, PA, USA

**PCV13** HOSPITAL TREATMENT PATTERNS AND RESOURCE UTILIZATION IN CONGESTIVE HEART FAILURE PATIENTS

Blount AC, Gaylord-Miles B, Hatch V, Gutierrez B, Premier, Inc, Charlotte, NC, USA

**PCV14** COST-EFFECTIVENESS OF THROMBOPROPHYLAXIS IN ACUTE-ILL MEDICAL INPATIENTS

McGarry L, Thompson D, Goldhaber S, Stokes M, Weinstein MC, Innovus Research, Inc, Medford, MA, USA; Brigham & Women’s Hospital, Boston, MA, USA; Harvard School of Public Health, Boston, MA, USA

**PCV15** TOTAL DIRECT MEDICAL AND DRUG COSTS OF NON-ADHERENCE TO STATIN THERAPY WITHIN THE FIRST YEAR OF TREATMENT

Peterson AM, Sanoski CA, McGhan WF, Philadelphia College of Pharmacy, Philadelphia, PA, USA
PCV16 DIFFERENCES IN HOSPITAL LENGTH-OF-STAY, CHARGES AND MORTALITY IN CONGESTIVE HEART FAILURE PATIENTS
Joshi AV1, D’Souza AO2, Madhavan SS1, West Virginia University/Pfizer, Morgantown, WV, USA; West Virginia University/Aventis, Morgantown, WV, USA; West Virginia University, Morgantown, WV, USA

PCV17 COST-EFFECTIVENESS OF RAMIPRIL (ALTACE) IN PATIENTS POST-REvascularization
Mallick R1, Fincher C1, Wyeth-Ayerst Research, Collegeville, PA, USA

PCV18 OVERWEIGHT AND OBESITY: THE COST TO SOCIETY AND THE ASSOCIATION WITH BODY MASS INDEX
Belisari A1, Carruba MO1, Mantovani LG2, University of Milan, Milan, Italy

PCV19 THE COST-EFFECTIVENESS ANALYSIS OF ASPIRIN FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE
Patel PA1, Hay J1, University of Southern California, Los Angeles, CA, USA

PCV20 A COST-EFFECTIVENESS ANALYSIS OF STATIN THERAPY IN A MANAGED CARE POPULATION
Bullano MF1, Willey VL1, Cziraky MJ1, Graham LI1, Corbelli JC1, Health Core, Newark, DE, USA; Pfizer, New York, NY, USA; Buffalo Cardiology and Pulmonary Associates, Williamsville, NY, USA

PCV21 COST-EFFECTIVENESS OF THE FIBRATES IN THE REDUCTION OF CORONARY HEART DISEASE EVENTS
Sterling KL1, Hay JW1, University of Southern California, Los Angeles, CA, USA

PCV22 AN EVALUATION OF THE CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH SWITCHING HYPERLIPIDEMIC PATIENTS TO PREFERRED STATIN THERAPY IN THE U.S. DEPARTMENT OF DEFENSE
Omar MA1, Wilson J1, University of Texas at Austin, Austin, TX, USA

PCV23 THE EFFECT OF β-BLOCKER AND ACE INHIBITOR THERAPY ON THE RISK OF HOSPITALIZATION AND RESOURCE UTILIZATION AMONG PATIENTS WITH CHF ENROLLED IN A MANAGED CARE ORGANIZATION
Abarca J1, Malone DC1, Armstrong EP1, University of Arizona, Tucson, AZ, USA

PCV24 APPLICATION OF THE COST OF OBESITY MODEL FOR COST BENEFIT ANALYSIS (CBA) OF SIBUTRAMINE AND ORLISTAT: A THIRD PARTY PAYER’S PERSPECTIVE
Sankaranarayanan J1, Viswanathan HN1, Bharmal M1, Shah B1, Murawski MM1, Purdue University, West Lafayette, IN, USA

PCV25 THE ECONOMIC IMPACTS OF TROUGHS: PEAK RATIO AND LIPOPOLYCHERITIS ON COST-EFFECTIVENESS OF ACE-INHIBITOR THERAPY FOR HYPERTENSION
Keufel EI1, Cifaldi M2, Bottema MF1, HERQuLES, Abt Associates Clinical Trials, Cambridge, MA, USA; Abbott Laboratories, Abbott Park, IL, USA; Abt Associates Clinical Trials, Bethesda, MD, USA

PCV26 FIRST RUSSIAN EXPERIENCE OF ASSESSING WILLINGNESS TO PAY: AVOIDING AMPUTATION IN CASE OF CRITICAL LIMB ISCHEMIA
Avzentieva M1, Vorobyov P1, Derkach E1, Gerasimov V1, Moscow Medical Academy, Moscow, Russia

PCV27 HEALTH ECONOMIC ASSESSMENT OF THE ARCTIC SUN™ MODEL 100 FOR TEMPERATURE MANAGEMENT IN OFF-PUMP CORONARY ARTERY BYPASS SURGERY
Gevitz FQ1, Kline R1, Brooks EA2, Lawten J1, Buckley AE1, Roberts SS1, Gao X1, PPD Development, Inc, Morrisville, NC, USA; Medivance, Inc, Louisville, CO, USA; PPD Development, Wilmington, NC, USA

PCV28 A COST ANALYSIS OF “BRIDGING THERAPY” FOR PATIENTS REQUIRING INTERRUPTION OF CHRONIC ANTICOAGULATION
Amorosi SL1, Thompson D2, Goldhaber SZ1, Tsilimingras K1, Fanikos J1, Weinstein MC2, Innovus Research, Inc, Medford, MA, USA; Brigham & Women’s Hospital, Boston, MA, USA; Harvard School of Public Health, Boston, MA, USA

PCV29 INFLUENCE OF COMORBID CONDITIONS IN THE HOSPITALIZATION OF ANGINA PATIENTS
Morris L1, Henderson SC1, von Allmen H1, Galey B1, Margolis J1, IMS Health, Plymouth Meeting, PA, USA

PCV30 ECONOMIC EVALUATION OF THREE MARKET LEADING HMG-CO-REDUCTASE INHIBITORS
Danielson DL2, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA

PCV31 COST-EFFECTIVENESS ANALYSIS OF THE ARCTIC SUN™ MODEL 100 FOR TEMPERATURE MANAGEMENT IN OFF-PUMP CORONARY ARTERY BYPASS SURGERY
Gevitz FQ1, Kline R1, Brooks EA2, Lawten J1, Gao X1, PPD Development, Morrisville, NC, USA; Medivance, Inc, Louisville, CO, USA; PPD Development, Wilmington, NC, USA

PCV32 COST OF ILLNESS AND RESOURCE UTILIZATION FOR PATIENTS SUFFERING MYOCARDIAL INFARCTION, WITH AND WITHOUT DEPRESSION
Taylor AT1, Athar MM1, Maclean JR1, Waller J1, Gottlieb M1, University of Georgia, Augusta, GA, USA; Medical College of Georgia, Augusta, GA, USA; Blue Cross and Blue Shield of Georgia, Atlanta, GA, USA

Quality of Life Presentations
PCV33 QUALITY OF LIFE QUESTIONNAIRES VALIDATION IN ESSENTIAL HYPERTENSIVES FROM AN ECONOMICALLY DISADVANTAGED COMMUNITY
Golubev SA1, Mily MN2, Vitebsk State Medical University, Vitebsk, Belarus; Vitebsk City Emergency Hospital, Vitebsk, Belarus

Health Policy Presentations
PCV34 PATTERNS OF ANTHYPERTENSIVE DRUG UTILIZATION AND CLINIC VISITS FOR ESSENTIAL HYPERTENSION: EVIDENCE FROM MEDICAL EXPENDITURE PANEL SURVEY, 1996
Guo D1, Fu AZ2, Liu GG3, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

PCV35 AN ASSESSMENT OF THE POTENTIAL UK POPULATION OF PEOPLE WITH TYPE 2 DIABETES ELIGBLE FOR PROPHYLAXIS WITH RAMIPRIL TO PREVENT CARDIOVASCULAR EVENTS
Chui MA1, Murray MD2, Midwestern University, Glendale, AZ, USA; Purdue University, West Lafayette, IN, USA

PCV36 MEDICATION ADHERENCE AND HEALTH CARE UTILIZATION IN HEART FAILURE PATIENTS
Chui MA1, Murray MD2, Midwestern University, Glendale, AZ, USA; Purdue University, West Lafayette, IN, USA

PCV37 EFFECT OF NON-ADHERENCE TO STATINS ON ASSOCIATED COST EFFECTIVENESS
Heer AM1, Barry M1, National Centre for Pharmacoconomics in Ireland, Dublin, Ireland

PCV38 MORE MEDICATIONS AND DISEASE STATES WERE RELATED TO AN INCREASE IN MEDICATION ADHERENCE AMONG PATIENTS AFTER A MYOCARDIAL INFARCTION
McBurney CR1, Erickson SR1, Kline-Rogers EM1, Smith DE1, Eagle KA1, University of Michigan and Pfizer Inc, Ann Arbor, MI, USA; University of Michigan, Ann Arbor, MI, USA
**Clinical Outcomes Presentations**

PAO1  CARDIORENAL EFFECTS AND COSTS OF COX-2 INHIBITORS IN A MANAGED CARE ORGANIZATION
Yu-Iseenberg KS*, Leslie RS, Chang EY, White TJ, Bailey KL, *Prescription Solutions, Costa Mesa, CA, USA; †Pharmacia Corporation, Peapack, NJ, USA

PAO2  TREATMENT PATTERNS OF CARE AND THE RISK OF SUBSEQUENT FRACTURES AMONG POSTOSTOROPIC WOMEN WITH INCIDENT FRACTURES
Yu-Iseenberg KS†, Ventura EP, Chang EY, White TJ, Kemner JE, Ogostalick A†, *Prescription Solutions, Costa Mesa, CA, USA; †Eli Lilly and Company, Indianapolis, IN, USA; ‡Eli Lilly and Company, Anaheim, CA, USA

**Economic Outcomes Presentations**

PAO3  MODELLED COST-UTILITY ANALYSIS OF ROFECOXIB AND TRADITIONAL NON-STEROIDAL THERAPIES FOR TREATMENT OF CHRONIC OSTEOARTHRITIS
Schulz M†: Noble I, Tilden D, Davey P, Crowley S, ’Merck Sharp & Dohme (Australia), Sydney, NSW, Australia; ’M-TAG, Sydney, NSW, Australia

PAO4  COST ANALYSIS OF A 12-WEEK CYCLE OF THERAPY WITH CELECOXIB VS CONVENTIONAL NSAIDS IN PATIENTS WITH OSTEOARTHRITIS
Chirolí S, Roggeri DP, Pharmacia Italia SpA, Milano, Italy

PAO5  AN ECONOMIC MODEL FOR GASTROINTESTINAL RISK STRATIFICATION COMPARING COX-2 INHIBITORS TO TRADITIONAL NSAIDS FOR ARTHRITIS TREATMENT
DeLattre ML‡, Schaefer MG†, Morreale AP, Plowman BK, ’VA San Diego Healthcare System/University of the Pacific, San Diego, CA, USA; ’VA San Diego Healthcare System, San Diego, CA, USA

PAO6  COST-EFFECTIVENESS OF BISPHOSPHONATE THERAPIES IN POSTMENOPAUSAL WOMEN: A THRESHOLD ANALYSIS
Burge RT†, Grima Di, Becker D, Tosteson AN, ’Procter & Gamble Pharmaceuticals, Mason, OH, USA; †Innovus Research Inc, Burlington, ON, Canada; ‡Dartmouth Medical School, Lebanon, NH, USA

PAO7  COST OFFSETS ARISING FROM THE USE OF MIACALCIN: PRELIMINARY RESULTS
Latimer E, Barbeau M, †Douglas Hospital Research Centre, McGill University, Verdun, QC, Canada; ‡Novartis Pharma Canada Inc, Dorval, QC, Canada

PAO8  FIRST-YEAR COSTS ASSOCIATED WITH NOVEL DISEASE-MODIFYING DRUGS IN THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS
Huse D†, Doyle J, †Pharametrics, Inc, Watertown, MA, USA; †Aventis Pharmaceuticals, Parsippany, NJ, USA

PAO9  AN ECONOMIC COMPARISON BETWEEN COX-2 INHIBITORS AND CONVENTIONAL NSAIDS IN THE TREATMENT PAIN RELATED TO ARTHRITIS
Beard S, Gaffney L, RTI Health Solutions, Manchester, UK

PAO10  COST-EFFECTIVENESS OF PHARMACEUTICAL TREATMENTS OF FRACTURE IN WOMEN WITH ESTABLISHED OSTEOPOROSIS IN HONG KONG
Zhang JX, Lau E, The Chinese University of Hong Kong, Shatin, NT, Hong Kong

PAO11  COST-EFFECTIVENESS OF VARIOUS TREATMENT STRATEGIES IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN POLAND
Orlevska E*, Lis J, †Medical University of Warsaw, Warsaw, Poland; †Eli Lilly Polska, Warsaw, Poland

**Quality of Life Presentations**

PAO12  WEB-BASED HEALTH STATUS ASSESSMENT OF A NATIONALLY REPRESENTATIVE SAMPLE OF ELDERLY OSTEOARTHRITIC PATIENTS
Madnani DM†, Nayak RA, Ward J, ’St. John’s University, Jamaica, NY, USA; †Knowledge Networks Inc, New York, NY, USA

PAO13  VALIDATION OF A PATIENT QUESTIONNAIRE TO ASSESS OSTEOPOROSIS-RELATED ATTITUDES, KNOWLEDGE AND BEHAVIOR
Brenneman SK†, Blau EM, Chen YT, Abbott TA, †Merck & Co., Inc, West Point, PA, USA; †Kaiser Permanente - Southern California, San Diego, CA, USA

PAO14  APPLICATION OF RASCH ANALYSIS IN COMPARISON OF SELF-ASSESSED HEALTH STATUS ACROSS TWO ARTHRITIS CONDITIONS USING A GENERIC HEALTH STATUS SURVEY
Dalal M†, Basu S, Smith E, University of Illinois at Chicago, Chicago, IL, USA

PAO15  IMPACT OF ETANERCEPT FOR RHEUMATOID ARTHRITIS (RA) ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND FUNCTIONAL STATUS IN A NATURALISTIC SETTING
Kamikawa BE†, Wanke LA, Immunex Corporation, Seattle, WA, USA

PAO16  RISK OF CLINICAL DEPRESSION IN ARTHRITIS: A WEB-BASED CO-ADMINISTRATION OF CESD-20 AND SF-36 TO A NATIONALLY REPRESENTATIVE ELDERLY SAMPLE
Nayak RA†, Madnani DM, Ward J, ’St. John’s University, Jamaica, NY, USA; †Knowledge Networks Inc, New York, NY, USA

**Health Policy Presentations**

PAO18  CALCIUM SUPPLEMENTATION AND REDUCTION IN ASSOCIATED FRACRES IN MEDICAID OSTEOPOROSIS PATIENTS
Dodd MA, Shah BM, Gupchup GV, Anderson JR, The University of New Mexico, Albuquerque, NM, USA

PAO19  UTILIZATION CHARACTERISTICS OF COX-2 INHIBITORS IN A LARGE MANAGED CARE HEALTH PLAN
Yu W, Kiang G, Etemad LR†, †WellPoint Pharmacy Management, West Hills, CA, USA; ‡University of Southern California, Los Angeles, CA, USA

PAO20  TRENDS OF ANTIRESORPTIVE THERAPIES USE AMONG WOMEN WITH PREVIOUS OSTEOPOROSIC FRACTURE
Perreault S†, Desgagné A, Boucher JM, Blais L, †Le Lorier J, Ste-Marie LG†, †Montreal University, Montreal, QC, Canada; ‡Montreal University, Montreal, QC, Canada; †University of Montreal, Montreal, QC, Canada

PAO21  MISSED OPPORTUNITIES IN PHARMACEUTICAL TREATMENT OF OSTEOPOROSIS IN POST-FRACTURE WOMEN
Wall MJ‡, Beilfuss CD†, Graff JS†, McBumney CR†, Fendrick AM†, †University of Michigan and Pfizer Inc, Ann Arbor, MI, USA; ‡University of Michigan, Ann Arbor, MI, USA

PAO22  REFILL ADHERENCE IN OSTEOPOROSIC WOMEN WITH PRIMARY AND SECONDARY FRACRE PREVENTION
Beilfuss CD†, Wall MJ†, Graff JS†, McBumney CR†, Fendrick AM†, †University of Michigan and Pfizer Inc, Ann Arbor, MI, USA; ‡University of Michigan, Ann Arbor, MI, USA
ASTHMA & RESPIRATORY DISEASES/DISORDERS

Clinical Outcomes Presentations

PAR1  ANALYSIS OF NASAL STEROID DOSING PATTERNS IN A LARGE SAMPLE FROM A PRESCRIPTION DATABASE
Moore E, Dept. of Defense Pharmacoeconomic Center, Fort Sam Houston, TX, USA

Economic Outcomes Presentations

PAR2  PREVALENCCE AND CORRELATES OF REDUCED PRODUCTIVITY ASSOCIATED WITH ALLERGIC RHINITIS IN THE WORKPLACE
Ershoff D1, Sullivan S2, Armstrong DS1, Integrated Therapeutics Group, Tarzana, CA, USA; ‘Institute for Health and Productivity Management, Scottsdale, AZ, USA; ‘Integrated Therapeutics Group, La Verne, CA, USA

PAR3  COSTS OF ALLERGIC RHINITIS IN THE U.S
Law AW, Reed SD, Schulman KA, Duke Clinical Research Institute, Durham, NC, USA

PAR4  ESTIMATION AND COMPARISON OF LOSS IN PRODUCTIVITY BY THE HUMAN CAPITAL AND FRICITION COST APPROACH IN PATIENTS WITH ASTHMA
Sarawate C, University of Illinois at Chicago, Chicago, IL, USA

PAR5  HEALTH CARE RESOURCES UTILIZATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Lathaine J1, Bradley-Kennedy C2, ‘University of Montreal, Montreal, QC, Canada; ‘Boehringer Ingelheim Canada Ltd, Burlington, QC, Canada

PAR6  ESTABLISHING THE RELIABILITY OF EVIDENCE FOR THE SIGNIFICANT IMPACT OF ALLERGIC RHINITIS ON HEALTH RELATED COSTS
Sullivan S1, Armstrong DS1, Ershoff D1, ‘Institute for Health and Productivity Management, Scottsdale, AZ, USA; ‘Integrated Therapeutics Group, La Verne, CA, USA

PAR7  ECONOMIC CONSEQUENCES OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN A NATIONAL SAMPLE OF US ADULTS
Sendersky V1, Law AW1, Gause D2, Sung J1, ‘Duke University/Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; ‘Duke University, Durham, NC, USA; ‘Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PAR8  COSTS AND BENEFITS ASSOCIATED WITH INITIATION OF FLUTICASONE VERSUS MONTELUKAST AS CONTROLLER THERAPY IN A MEDICAID ASTHMATIC POPULATION
Balkrishnan R1, Camacho F1, Schechter MS2, Pleasant RA1, Bowton DL1, ‘Wake Forest University School of Medicine, Winston-Salem, NC, USA; ‘Campbell University School of Pharmacy, Buies Creek, NC, USA

PAR9  COSTS AND BENEFITS ASSOCIATED WITH ADDITION OF Salmeterol Versus Montelukast to Inhaled Corticosteroid Therapy in a Medicaid Asthmatic Population
Balkrishnan R1, Camacho F1, Schechter MS2, Pleasant RA1, Bowton DL1, ‘Wake Forest University School of Medicine, Winston-Salem, NC, USA; ‘Campbell University School of Pharmacy, Buies Creek, NC, USA

PAR10 RESOURCE UTILIZATION FOR INPATIENT ASTHMA CARE IN CHILDREN AND ADULTS: AN ANALYSIS OF HCUP DATA
Hassan MK, Amonkar MM, West Virginia University, Morgantown, WV, USA

PAR11 COST-UTILITY ANALYSIS OF MIDDLE SEVERE ASTHMA WITH SODIUM CROMOGLYCATE AND SODIUM NEDOCROMIL
Prosekova E, Geltzer B, Dercach V, Bogdanovskiy P, Frisman M, ‘Vladivostok State Medical University, Vladivostok, Russia; ‘Child’s Municipal Asthma-centre, Vladivostok, Russia

PAR12 ESTIMATES OF THE COST OF ASTHMA IN A EMPLOYER POPULATION
Athery AJ1, Williams SG2, ‘Emory University / Centers for Disease Control, Atlanta, GA, USA; ‘Centers for Disease Control, Atlanta, GA, USA

PAR13 THE COST OF ASThma IN CATALONIA: A DESCRIPTIVE AND MODELLING APPROACH
Rovira J1, Abbas I2, Hermida H1, ‘The World Bank, Washington, DC, USA; ‘SOIKOS, Barcelona, Spain

PAR14 USE OF AN INTERACTIVE VOICE RESPONSE SYSTEM (IVRS) FOR LONG-TERM RESOURCE USE DATA COLLECTION
O’Brien J1, Lordan N, Ward A, Caro Research Institute, Concord, MA, USA

PAR15 IMPACT OF ALLERGY AND ASThma BOTH SEPARATELY AND CONCOMITANTLY ON LOST HOURS FROM WORK
Armstrong DS1, Ershoff D1, Sullivan S2, ‘Integrated Therapeutics Group, La Verne, CA, USA; ‘Integrated Therapeutics Group, Tarzana, CA, USA; ‘Institute for Health and Productivity Management, Scottsdale, AZ, USA

Quality of Life Presentations

PAR16 CULTURAL ADAPTATION AND VALIDATION OF CHILDHOOD ASTHMA QUESTIONNAIRE VERSION B (CAQ-B) FOR SINGAPORE CHILDREN
Chong LY1, Chay OM2, Goh A1, Seng YC2, Li SC2, ‘National University of Singapore, Department of Pharmacy, Singapore, Singapore; ‘KK Women’s and Children’s Hospital, Singapore, Singapore

Health Policy Presentations

PAR17 CLINICAL, PUBLIC HEALTH, AND ECONOMIC ISSUES ASSOCIATED WITH SWITCHING SECOND-GENERATION ANTIHISTAMINES FROM PRESCRIPTION TO OVER-THE-COUNTER
Prasad M1, Shih YCT, Luce BR, MEDTAP International Inc, Bethesda, MD, USA

PAR18 PREGNANCY OUTCOMES IN WOMEN TAKING ANTI-ASTHMATIC MEDICATIONS IN THE GEORGIA MEDICAID POPULATION
Joseph GJ1, Kotzan JA2, Wade WE3, ‘Hines VA Hospital, Hines, IL, USA; ‘University of Georgia, Athens, GA, USA; ‘University of Georgia College of Pharmacy, Athens, GA, USA

CANCER

Clinical Outcomes Issues

PCN1 LONG-TERM BENEFITS OF CHEMOPREVENTIVE TAMOXIFEN AND ROUTINE MAMMOGRAPHY SCREENING IN WOMEN WHO ARE AT INCREASED RISK OF BREAST CANCER
Borker R, Madhavan S, Simon K, Higa G, Amonkar M, Scott V, West Virginia University, Morgantown, WV, USA

PCN2 AN INTERIM COST AND OUTCOME COMPARISON ALONGSIDE A PROSPECTIVE RANDOMIZED CLINICAL TRIAL COMPARING EARLY INTENSIFICATION WITH BONE MARROW TRANSPLANTATION (BMT) TO CONVENTIONAL DOSE CHEMOTHERAPY FOR PREVIOUSLY UNTREATED PATIENTS WITH AGGRESSIVE NON-HODGKIN’S LYMPHOMA
Adamus AT, Arbuckle RB, King KM, Rodriguez MA, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

PCN3 COLLECTION OF INFECTIOUS DISEASE AND ECONOMIC OUTCOMES FOR NON-HODGKIN’S LYMPHOMA AND MULTIPLE MYELOMA PATIENTS ADMITTED FOR INFECTIOUS COMPLICATIONS UTILIZING A PALMTM HANDHELD
King KM, Wood AM, Arbuckle RB, Adams AT, Hagemeister FB, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Economic Outcomes Presentations

PCN4 RETROSPECTIVE COST ANALYSIS OF GEMZAR™ IN COMBINATION WITH CISPLATIN IN NON-SMALL CELL LUNG CANCER COMPARED TO OTHER COMBINATION THERAPIES IN GERMANY
Kielhorn A1, Maniakakis N1, Aristides M1, Lees M1, Tilden D1, Eli Lilly, Windlesham, Surrey, UK; 2Medical Technology Assessment Group, London, UK; 3Medical Technology Assessment Group, Chatswood West, NSW, Australia

PCN5 PROSPECTIVE HEALTH ECONOMIC EVALUATION OF MEDICAL CARE FOR PATIENTS WITH MALIGNANT LYMPHOMAS IN GERMANY: FIRST RESULTS
Reis A1, Gandjour A1, Paulus U1, Franklin J1, Lauterbach K1, Diehl V1, Walshe R1, 1First Department of Internal Medicine, University of Cologne, Cologne, Germany; 2Institute of Health Economics and Clinical Epidemiology, University of Cologne, Cologne, Germany

PCN6 FAMILY CAREGIVING COSTS FOR CANCER PATIENTS: A MULTI-EMPLOYER ANALYSIS
Cremieux P1, Duh MS1, Birnbaum H1, Blasi M1, Gardner H1, Analysis Group/Economics, Cambridge, MA, USA; 2Ortho Biotech Products, LP, Raritan, NJ, USA; 3Options and Choices Inc, Cheyenne, WY, USA

PCN7 COLORECTAL CANCER SCREENING: A COST-EFFECTIVENESS MODEL COMPARING VIRTUAL COLONOSCOPY AND CONVENTIONAL COLONOSCOPY
Patel BV1, Hay JW1, University of Southern California, Los Angeles, CA, USA

PCN8 COST-EFFECTIVENESS ANALYSIS OF LHRH AGONISTS IN THE TREATMENT OF METASTATIC PROSTATE CANCER
Iskedjian M1, Hemels M1, Iscoe N1, Fleshner N1, Einanson T1, 1Pharmacies Research and Consulting Inc, Oakville, ON, Canada; 2University of Toronto, Toronto, ON, Canada; 3Toronto-Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; 4Sunnybrook and Women’s Health Sciences Center, Toronto, ON, Canada

PCN9 PHARMACOECONOMIC ANALYSES OF AVAILABLE CHEMOTHERAPEUTIC AGENTS FOR THE MANAGEMENT OF ADVANCED COLORECTAL CANCER
Kamal-Bahi S1, Doshi JA1, Grossman P2, University of Maryland, Baltimore, MD, USA; 2Bristol-Myers Squibb Company, Wallingford, CT, USA

PCN10 A COMPREHENSIVE INTERNET DATABASE OF THE COST-EFFECTIVENESS OF CANCER PREVENTION, SCREENING, AND TREATMENT
Tengs TO1, Chen LL1, Williams NL1, Emptage NP1, Nguyen CT1, Sepe J1, Mendoza LA1, Health Priorities Research Group, University of California, Irvine, CA, USA

PCN11 COSTS AND CHARACTERISTICS OF PATIENTS WHO UNDERGO BONE MARROW TRANSPLANT (BMT)
Friedman JY1, Reed SD2, Glendenning A1, Schulman KA1, Duke Clinical Research Institute, Durham, NC, USA; 2Novartis Pharmaceuticals, East Hanover, NJ, USA

PCN12 AN UPDATED RISK THRESHOLD MODEL FOR G-CSF PROPHYLAXIS USE IN CANCER CHEMOTHERAPY: INCORPORATION OF PATIENT OUT-OF-POCKET AND INDIRECT COSTS
Cosler LE1, Agboola O1, Calhoun EA1, Lyman GH1, 1Albany College of Pharmacy, Albany, NY, USA; 2Albany Medical Center, Albany, NY, USA; 3Northwestern University Medical School, Chicago, IL, USA

PCN13 COST-EFFECTIVENESS OF RITUXIMAB IN DIFFUSE LARGE B CELL LYMPHOMA
Best JH1, Hornberger J1, Omnes LF1, Coiffier B2, Acumen, LLC, Burlingame, CA, USA; 2Acumen, LLC and Stanford University School of Medicine, Burlingame, CA, USA; 3Annie Chicoye Economics, Neuilly Sur Seine, France; 4Centre Hospitalier Lyon Sud, Pierre Bénéte, France

Quality of Life Presentations

PCN17 SIDE EFFECTS OF CHEMOTHERAPY AMONG PATIENTS WITH OVARIAN CANCER: IMPLICATIONS FOR QUALITY OF LIFE
Lewis BE1, Silberman C1, Janine M1, Heyes A2, 1Focus Managed Research, Worcester, MA, USA; 2AstraZeneca, Wilmington, DE, USA; 3Focus Managed Research, Longmeadow, MA, USA; 4AstraZeneca UK Limited, Macclesfield, UK

PCN18 AN APPRAISAL OF TREATMENT SATISFACTION AND PATIENT PREFERENCE ASSESSMENTS IN PATIENTS DIAGNOSED WITH CANCER
McBurney CR1, Coombs JH2, Hsu MA2, Aberz D1, Keininger D2, Copley-Merriman C1, University of Michigan and Pfizer Inc, Ann Arbor, MI, USA; 2Pfizer Inc, Ann Arbor, MI, USA; 3Pfizer Inc, Groton, CT, USA; 4Mapi Values, Cheshire, UK; 5Mapi Values, Boston, MA, USA

PCN19 USE OF THE EUROQOL VISUAL ANALOGUE SCALE IN ASSESSING LONGITUDINAL CHANGES IN QUALITY OF LIFE IN CANCER PATIENTS: A COMPARISON WITH SUBSCALES OF THE MEDICAL OUTCOMES SURVEY SHORT FORM-36
Castel LD1, Reed SD1, Weinfurt KP2, Li Y1, Law AW2, Meropol NJ2, Schulman KA1, Duke Clinical Research Institute, Durham, NC, USA; 2Fox Chase Cancer Center, Philadelphia, PA, USA

Health Policy Presentations

PCN20 ASSOCIATION OF INSURANCE COVERAGE AND EPIDEMIOLOGICAL RISK FACTORS ON GASTRIC CANCER SURGERY
Copley-Merriman C2, 1University of Michigan and Pfizer Inc, Ann Arbor, MI, USA; 2Pfizer Inc, Groton, CT, USA; 3Options and Choices Inc, Cheyenne, WY, USA

DIABETES

Clinical Outcomes Presentations

PDB1 COMPARATIVE ANALYSIS OF PERSISTENCE ON THERAPY USING GLIPIZIDE GITS, GLIPIZIDE, AND GLYBURIDE AMONG NEWLY TREATED TYPE 2 DIABETES PATIENTS
Harley C1, Cantor ES2, Misra A1, Nelson M1, Ingenix Pharmaceutical Services, Eden Prairie, MN, USA; 2Pfizer, Inc, New York, NY, USA

PDB2 A RETROSPECTIVE COHORT STUDY OF DIABETES MELLITUS AND ANTIPSYCHOTIC TREATMENT IN THE UNITED KINGDOM
Cavazzoni P1, Hornbuckle K1, Wu J2, Breier A1, Kotsanos J1, Holman R1, 1Lilly Research Laboratories, Indianapolis, IN, USA; 2University of Michigan, Ann Arbor, MI, USA; 3University of Oxford, Oxford, Oxford, UK
Economic Outcomes Presentations

PDB5 THE ECONOMIC VALUE OF NON-DIHYDROPYRIDINE VS. DIHYDROPYRIDINE CALCIUM BLOCKER/ACE INHIBITOR COMBINATIONS IN PATIENTS WITH TYPE-II DIABETES Keuffel EL, Cifaldi M*, Botteman MF*, HERQuLES, Abt Associates Clinical Trials, Cambridge, MA, USA; 2Abbott Laboratories, Abbott Park, IL, USA; 3Abt Associates Clinical Trials, Bethesda, MD, USA

PDB6 PREVENTION OF TYPE 2 DIABETES IN THE USA: COST-EFFECTIVENESS ISSUES Palmer AJ, Roze S, CORE Center for Outcomes Research, Basel, Switzerland

PDB7 FINANCIAL IMPACT OF IMPROVED DIABETES MANAGEMENT THROUGH BLOOD KETONE TESTING AND OPTIMIZED GLYCEMIC CONTROL Luo MP, Rao S*, Ashraf T*, Abbott Laboratories, Abbott Park, IL, USA; 2Abbott Laboratories, Bedford, MA, USA

PDB8 ECONOMIC COMPARISON OF SIX FIRST-LINE DRUG STRATEGIES IN TYPE 2 DIABETES USING A MONTE CARLO SIMULATION MODEL Stephens JM*, Ramsdell JW, Braunstein S*, Bell CF, Botteman MF, Brandt S*, Devine ST*, Abt Associates Clinical Trials, Bethesda, MD, USA; 2University of California San Diego Medical Center, San Diego, CA, USA; 3University of Pennsylvania Health System, Philadelphia, PA, USA; 4Pfizer Inc, New York, NY, USA

PDB9 A RETROSPECTIVE ANALYSIS OF SHORT-TERM COSTS AND UTILIZATION ASSOCIATED WITH GLYCEMIC CONTROL AMONG TYPE2 DIABETIC PATIENTS WITHIN A MANAGED CARE

PDB10 INCIDENCE, MANAGEMENT AND COST OF CARDIO-VASCULAR AND RENAL COMPLICATIONS IN FRENCH TYPE 2 DIABETIC PATIENTS Fagnani F, Souchet T, Labeled D, CEMKA, Bourg la Reine, France; 2Merck Sharp & Dohme - Chibret, Paris, France; 3IMS - Health, Nanterre, France

PDB11 HEALTH SERVICES COST AND UTILIZATION COMPARISONS AMONG LISPRO AND NON-LISPRO REGULAR INSULIN USERS Hall J*, Summers KH, Obenchain RL, Ingenix Pharmaceutical Services, Eden Prairie, MN, USA; 2Eli Lilly & Company, Indianapolis, IN, USA

Quality of Life Presentations

PDB12 FACTORS PREDICTING SELF-RATED HEALTH AND PATIENT SATISFACTION IN A MANAGED CARE DIABETES POPULATION Nau DP, Kumar RN, University of Michigan, Ann Arbor, MI, USA

Health Policy Presentations

PDB13 TRENDS IN INSULIN THERAPY FOR TREATMENT OF TYPE-2 DIABETES MELLITUS Conklin JE, Neslan CA, Cohen F, Song X, The MEDSTAT Group, Santa Barbara, CA, USA; 2Pharmaceuticals Group Strategic Marketing, Raritan, NJ, USA; 3RW Johnson Pharmaceutical Research Institute, Raritan, NJ, USA

PDB14 PATIENT’S PERSPECTIVE OF HYPOGLYCEMIA AS AN ADVERSE EFFECT OF ORAL ANTIDIABETIC MEDICATIONS Salas M, Caro JJ, Sung J, Garfield F, Caro Research Institute, Concord, MA, USA; 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PDB15 USING SURVIVAL MODELS TO PREDICT THE START OF INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS Rosenblum MS, Dirani R, Bowman A, Integrell, Latham, NY, USA; 2Aventis Pharmaceuticals, Bridgewater, NJ, USA; 3Union College, Schenectady, NY, USA

METHODOLOGY ISSUES

PMI1 FROM HEALTH-RELATED QOL TO UTILITY - IS THERE A WAY? Svensson K*, Szende A*, Stähl E, Lundbäck B*, AstraZeneca R&D Lund, Sweden, Lund, Sweden; 2Medtap International, Jisp, Netherlands; 3University Hospital, Umeå, Sweden

PMI2 ESTIMATING PREVALENCE AND SURVIVAL BY STAGE OF CANCER FROM THE US SEER DATABASE: COLORECTAL CANCER Koo LC, Lally CA, AstraZeneca, Wilmington, DE, USA; 2Emory University, Atlanta, GA, USA

PMI3 DEVELOPMENT OF DESCRIPTIONS OF TREATMENTS FOR COLORECTAL CANCER FOR USE IN PREFERENCE MEASUREMENT Wild D*, Grove A*, Hakim Z*, Kind P*, Oxford Outcomes, Headington, Oxford, UK; 2Roche Pharmaceuticals, Nutley, NJ, USA; 3University of York, Heslington, York, UK


PMI5 FACTORS FOR THE VARIATION IN THE PREVALENCE OF ARTERIAL PERIPHERIAL DISEASE – STUDY IMPLICATIONS FOR ORGANIZATION
Chen KS, Melikian CA, Chang EY, White TJ, Prescription Solutions, Costa Mesa, CA, USA

PMI6 ESTIMATING THE BENEFITS OF ANTHYPERTENSIVE THERAPY: AN ASSESSMENT OF PULSE PRESSURE Grover SA, Brewer C, Coupal L, Zowall H, Pradhan AA, McGill University, Montreal, QC, Canada; 2Bristol-Myers Squibb Pharmaceuticals Group, Montreal, QC, Canada

PMI7 MODELING ON THE STOCHASTIC FRONTIER: COST OF TREATMENT FOR ACUTE DECOMPENATED HEART FAILURE de Lisseovoy G, Stier DM, Ciesla G, Straussler B, Burger AJ, 2MEDTAP International, Bethesda, MD, USA; 3Eureka Research Inc, San Francisco, CA, USA; 4Scios Inc, Sunnyvale, CA, USA; 5Beth Israel Deaconess Medical Center, Boston, MA, USA

PMI8 VALIDATION OF COST ESTIMATION TECHNIQUE FOR HOSPITALIZATIONS FOR USE IN MULTINATIONAL ECONOMIC EVALUATIONS Reed SD, Friedman JY, Gnanasakthy A, Schulman KA, Duke Clinical Research Institute, Durham, NC, USA; 2Novartis Pharmaceutical Corp, East Hanover, NJ, USA


OUTCOMES RESEARCH
Wang Y, Pfizer Inc, Ann Arbor, MI, USA

PMI6 ESTIMATING THE BENEFITS OF ANTHYPERTENSIVE THERAPY: AN ASSESSMENT OF PULSE PRESSURE Grover SA, Brewer C, Coupal L, Zowall H, Pradhan AA, McGill University, Montreal, QC, Canada; 2Bristol-Myers Squibb Pharmaceuticals Group, Montreal, QC, Canada

PMI7 MODELING ON THE STOCHASTIC FRONTIER: COST OF TREATMENT FOR ACUTE DECOMPENATED HEART FAILURE de Lisseovoy G, Stier DM, Ciesla G, Straussler B, Burger AJ, 2MEDTAP International, Bethesda, MD, USA; 3Eureka Research Inc, San Francisco, CA, USA; 4Scios Inc, Sunnyvale, CA, USA; 5Beth Israel Deaconess Medical Center, Boston, MA, USA

PMI8 VALIDATION OF COST ESTIMATION TECHNIQUE FOR HOSPITALIZATIONS FOR USE IN MULTINATIONAL ECONOMIC EVALUATIONS Reed SD, Friedman JY, Gnanasakthy A, Schulman KA, Duke Clinical Research Institute, Durham, NC, USA; 2Novartis Pharmaceutical Corp, East Hanover, NJ, USA


POSTER PRESENTATIONS – SESSION II
**PMI39** THE USE OF DRG-RELATED DATA ON KNEE PROCEDURES IN THE ANALYSIS OF UTILISATION OF RESOURCES BETWEEN BELGIAN HOSPITALS

Putman K1, Corens D1, Nieberding P2, Schots J1, Beeckmans J1, 1Centre of Health Economics and Hospital Policy - Vrije Universiteit Brussel, Brussel, Belgium; 2University Hospital - Vrije Universiteit Brussel, Brussel, Belgium; 1Centre of Health Economics and Hospital Policy - University Hospital, Vrije Universiteit Brussel, Brussel, Belgium

**PMI40** THE POTENTIAL IMPORTANCE OF DATA SOURCES AND ANALYTIC APPROACHES TO THE EXTERNAL VALIDITY OF ECONOMIC STUDIES

Chumney ECG1, Simpson KN1, Medical University of South Carolina, Charleston, SC, USA

**PMI41** SATISFACTION WITH SMOKING CESSION TREATMENTS – A SYSTEMATIC REVIEW OF THE DIMENSIONS

Holliford DA1, Virginia Commonwealth University, Richmond, VA, USA

**PMI42** DESIGN AND VALIDITY OF AUTOMATED HEALTH CARE DATA SCREENS TO DETECT IN-HOSPITAL ADVERSE DRUG EVENTS

Sauer RC1, Winterstein AG1, Mattenklotz AM1, University of Florida, Gainesville, FL, USA

**MENTAL HEALTH**

(including Alzheimer's Disease, Dementia, Alcoholism, and Attention Deficit Disorder)

**Clinical Outcomes Presentations**

**PMH1** USEFULNESS OF ELECTRONIC COMPLIANCE DATA IN AN EFFECTIVENESS TRIAL

Cramer J1, Rosenheck R1, Krystal J1, Kirk G1, Krol W1, 1Yale University School of Medicine, West Haven, CT, USA; 2Dept. of Veterans Affairs, Perry Point, MD, USA

**PMH2** ESTABLISHING THE EXPECTED RATE OF COGNITIVE DECLINE IN ALZHEIMER’S DISEASE?

Caro JJ1, Ward A1, Kelley H1, Ishak K1, Raggio G1, Robinson K1, Molloy W1, 1Caro Research Institute, Concord, MA, USA; 2Caro Research Institute, Dorval, QC, Canada; 1Janssen-Ortho Inc, Toronto, ON, Canada; 2McMaster University, Hamilton, ON, Canada

**PMH3** ANTIPSYCHOTIC AGENTS AND THE RISK OF DEVELOPING DIABETES

Caro JJ1, Ward A1, Levinton C1, Robinson K1, 1Caro Research Institute, Concord, MA, USA; 2Janssen-Ortho Inc, Toronto, ON, Canada

**PMH4** SUPPLEMENTAL ANALYSIS OF THE QUETIAPINE EXPERIENCE WITH SAFETY AND TOLERABILITY (QUEST) STUDY

White R1, Simons WR1, Yu E1, 1AstraZeneca, Wilmington, DE, USA; 2Global Health Economics & Outcomes Research, Inc, Summit, NJ, USA

**PMH5** EFFICACY OF NURSE TELEHEALTH CARE AND PEER SUPPORT IN AUGMENTING TREATMENT OF DEPRESSION IN PRIMARY CARE

Hunkeler EM1, Meresman JF1, Heagreaves WA1, 1Kaiser Permanente, Oakland, CA, USA; 2Kaiser Permanente, Northern California, Santa Clara, CA, USA; 3University of California, San Francisco, San Francisco, CA, USA

**PMH6** RISK OF DIABETES FOR INDIVIDUALS WITH SCHIZOPHRENIA TREATED WITH ANTIPSYCHOTICS

Zhao Z1, Loosbrock Di1, Eli Lilly and Company, Indianapolis, IN, USA

**PMH7** OUTCOMES AND COST OF TREATMENT WITH RISPERIDONE VERSUS OLANzapine AMONG PATIENTS WITH CHRONIC SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDERS

Vera-Lionch M1, Oster G1, Delea T1, Rupnow M1, Grogg A1, 1Policy Analysis Inc, Brookline, MA, USA; 2Janssen Pharmaceutical Products, L.P, Titusville, NJ, USA

**Economic Outcomes Presentations**

**PMH8** ONE YEAR HOSPITALIZATION RATES IN PATIENTS WITH SCHIZOPHRENIA DURING LONG-TERM TREATMENT WITH LONG-ACTING RISPERIDONE

Chue PS1, Devos E1, Duchesne IY1, Leal AR1, Mehert A1, 1University of Alberta, Edmonton, Alberta, Canada; 2SGS Biopharma SA, Wavre, Belgium; 3Janssen Pharmaceutica NV, Beerse, Belgium

**PMH9** THE DIRECT AND INDIRECT ECONOMIC COSTS OF PSYCHOTIC DISORDERS TO BOTH PATIENTS AND CAREGIVERS

Simons WR1, White R1, Bassi R1, 1Global Health Economics & Outcomes Research, Inc, Summit, NJ, USA; 2AstraZeneca, Wilmington, DE, USA

**PMH10** THE BURDEN OF DEPRESSION IN CANADA

Desjardins B1, Laurier C1, 1University of Montreal, Faculty of Pharmacy, Merck Frost Canada Ltd, Kirkland, QC, Canada; 2University of Montreal, Montreal, QC, Canada

**PMH11** A SWEDISH PHARMACOECONOMIC EVALUATION OF ESCITALOPRAM, A NEW SSRi: COMPARISON OF COST-EFFECTIVENESS BETWEEN ESCITALOPRAM, CITALOPRAM, FLUOXETINE AND VENLAFAXINE

François C1, Henriksen F1, Touni M1, Kornfeld A1, 1Lundbeck SA, Paris, France; 2Stockholm School of Economics, Stockholm, Sweden

**PMH12** EMPLOYMENT-RELATED COSTS OF INFORMAL CAREGIVING FOR ALZHEIMER’S DISEASE PATIENTS: EFFECTS OD RIVASTIGMINE TREATMENT

Gianfrancesco FD1, Chang S1, Wang RH1, 1HECON Associates, Inc, Montgomery Village, MD, USA; 2Novartis Pharmaceutical Corporation, East Hanover, NJ, USA

**PMH13** IMPACT OF ANXIETY ON ABSENTEEISM: ESTIMATES FROM THE 1997 MEDICAL EXPENDITURE PANEL SURVEY

Graff JS1, Taylor TN1, McBurney CR1, 1University of Michigan/ Pfizer Pharmaceuticals, Ann Arbor, MI, USA; 2Pfizer Inc, Ann Arbor, MI, USA

**PMH14** HEALTH CARE EXPENDITURES OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND POST TRAUMATIC STRESS DISORDER

Crystal-Peters J1, Chang S1, Long S1, The MEDSTAT Group, Washington, DC, USA

**PMH15** PREVALENCE AND COSTS OF TREATMENT-RESISTANT DEPRESSION IN A CANADIAN CLAIMS DATABASE

Gilsenan AW1, Hopkins JS1, Sherrill BH1, Corey-Lisle PK1, Longo CJ1, Raskin J3, 1RTI Health Solutions, Research Triangle Park, NC, USA; 2Eli Lilly and Company, Indianapolis, IN, USA; 3Eli Lilly Canada, Scarborough, ON, Canada

**PMH16** PREVALENCE AND COSTS OF ACCIDENTS AMONG ATTENTION-DEFICIT/HYPERACTIVITY DISORDER PATIENTS

Swensen A1, Birnbaum H1, Ben-Hamadi R1, Greenberg P1, Cremieux PY1, 1Eli Lilly and Company, Indianapolis, IN, USA; 2Analysis Group/Economics, Cambridge, MA, USA

**PMH17** ECONOMICS OF PERSISTENCE WITH INITIALLY PRESCRIBED ANTIPSYCHOTIC IN OLDER PSYCHOTIC PATIENTS AND IN PATIENTS WITH BIPOLAR DISORDER

White R1, Simons WR1, Bassi R1, 1AstraZeneca, Wilmington, DE, USA; 2Global Health Economics & Outcomes Research, Inc, Summit, NJ, USA

**PMH18** UTILIZATION AND COST OF RESOURCES IN BIPOLAR PATIENTS RECEIVING ATYPICAL ANTIPSYCHOTICS

Meletiche DM1, Bolge SC1, Lasser R1, 1Janssen Pharmaceutical, Titusville, NJ, USA; 2Consumer Health Sciences, Princeton, NJ, USA

**PMH19** USING A COMMUNITY SAMPLE TO DERIVE UTILITY VALUES OF SCHIZOPHRENIA TREATMENT OUTCOMES FROM A TIME TRADE-OFF METHODOLOGY

Zhao Z1, Loosbrock Di1, Eli Lilly and Company, Indianapolis, IN, USA
PMH20  
FACTORS IMPACTING COST OF TREATMENT FOR DEPRESSION  
Paramore C, Olufade A, Revicki D, MEDTAP International, Bethesda, MD, USA; Pfizer, Inc, New York, NY, USA

PMH21  
INPATIENT MEDICATION UTILIZATION AND COSTS OF RISPERIDONE, OLANZAPINE AND QUETIAPINE: A RETROSPECTIVE CHART ABSTRACTION STUDY  
Nextorons D, Irish W, Lopez R, Degen K, Swann A, Grogg A, Myrie L, Bell T, Young AL, Girts T, Potthast R, RTI Health Solutions, Research Triangle Park, NC, USA; Middlesex Hospital, Middletown, CT, USA; The University of Texas Health Science Center at Houston, Houston, TX, USA; Janssen Pharmaceutica, Titusville, NJ, USA

PMH22  
ECONOMIC OUTCOMES ASSOCIATED WITH OLANZAPINE VERSUS DIVALPROEX TREATMENT FOR ACUTE MANIA: RESULTS FROM A RANDOMIZED CLINICAL TRIAL  
Zhu B, Baker R, Altshtuler L, Zarate C, Ketter T, Lage M, Tunis S, Shi L, Tohen M, Lilly Research Laboratories, Indianapolis, IN, USA; National Institute of Mental Health, Bethesda, MD, USA; Stanford University, Stanford, CA, USA; HealthOutcomes Research, Groton Long Point, CT, USA

PMH23  
THE COST CONSEQUENCES OF CONTINUED TREATMENT-RESISTANCE IN DEPRESSION  
Ozminkowski RJ, Russell JM, Crown WH, Hawkins K, Orsini L, Finkelstein S, Berndt E, The MEDTAP Group, Inc, Ann Arbor, MI, USA; Cyberonics, Inc, Houston, TX, USA; The MEDTAP Group, Cambridge, MA, USA; Massachusetts Institute of Technology, Cambridge, MA, USA

PMH24  
MODELING THE ECONOMIC IMPACT OF GALANTAMINE TREATMENT IN PATIENTS WITH ALZHEIMER’S DISEASE IN DIFFERENT HEALTH CARE SYSTEMS  
Caro J, Salas M, Ward A, Getsios D, Migliaccio-Walle K, Garfield P, Caro Research Institute, Concord, MA, USA; Caro Research Institute, Dorval, QC, Canada

PMH25  
COST IMPACT OF DEPOT DOSAGE FORMS OF ATYPICAL VERSUS TYPICAL ANTI psychoticS  
Krlejic I, MacKeigan L, Einaron T, Remington G, Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada; Centre for Addiction and Mental Health, Toronto, ON, Canada

PMH26  
A COMPARISON OF RISPERIDONE AND OLANZAPINE MENTAL HEALTH COSTS FOR MANAGED CARE PATIENTS WITH SCHIZOPHRENIA  

PMH27  
SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM (SCAP): THE IMPACT OF CLINICAL AND FUNCTIONAL CHARACTERISTICS AND ANTI psychotic MEDICATION TREATMENT ON OUTPATIENT AND INPATIENT PSYCHIATRIC UTILIZATION  
Russo P, Palmer LA, Vasey J, The MEDTAP Group, Inc, Washington, DC, USA; The Pennsylvania State University, State College, PA, USA

PMH28  
IS DONEPEZIL COST-EFFECTIVE IN THE TREATMENT OF ALZHEIMER’S DISEASE (AD)?  
Sobolewski M, Kuzniar J, Sliwinski J, Marc M, University of Technology, Rzeszow, Poland; District Hospital No2, Rzeszow, Poland; Independent Centre for Economic and Pharmaceutical Research, Warsaw, Poland

Quality of Life Presentations

PMH29  
THE EFFECTS OF PANAX GINSENG ON QUALITY OF LIFE: A PILOT STUDY  
Reddy P, Ellis J, University of Connecticut, Storrs, CT, USA

PMH30  
INFLUENCE OF CAREGIVING ON HEALTH STATUS OF DEMENTIA CAREGIVERS  
Mulchandani D, Nayak RA, St. John’s University, Jamaica, NY, USA

PMH31  
CATEGORYICAL RESPONSE DEFINES TREATMENT EFFECTIVENESS OF OLANZAPINE VERSUS RISPERIDONE IN THE IMPROVEMENT OF NEGATIVE SYMPTOMS AND QUALITY OF LIFE IN SCHIZOPHRENIA  
Kinon BJ, Zhao Z, Lilly Research Lab, Indianapolis, IN, USA; Eli Lilly and Company, Indianapolis, IN, USA

PMH32  
THE IMPACT OF DULOXETINE FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER ON THE QUALITY OF LIFE IN DEPRESSION SCALE  
Robinson RJ, Obenchian RL, Crogan TW, Eli Lilly and Company, Indianapolis, IN, USA

PMH33  
QUALITY OF LIFE IN SCHIZOPHRENIA: THE RELATIONSHIP BETWEEN PARTICIPANT SELF-REPORT AND CLINICAL ASSESSMENT  
Russo P, Smith MW, The MEDTAP Group, Inc, Washington, DC, USA; VA Palo Alto Health Care System, Menlo Park, CA, USA

PMH34  
PSYCHOMETRIC EVALUATION OF THE MODIFIED STRAIN IN NURSING CARE ASSESSMENT SCALE  
Ciesla G, Frank L, Kleinman L, Brodaty H, Rupnow M, MEDTAP International, Bethesda, MD, USA; University of New South Wales, Sydney, Australia; Janssen Pharmaceutica Products, L.P, Titusville, NJ, USA

Health Policy Presentations

PMH35  
LABOR SUPPLY OF POOR RESIDENTS IN METROPOLITAN MIAMI: THE ROLE OF DEPRESSION AND THE CO-MORBID EFFECTS OF DRUG USE  
Alexandre PK, French M, University of Miami, Miami, FL, USA

PMH36  
IMPACT OF PRIMARY PAYER TYPE ON ACCESS TO ANTIDEPRESSANT PHARMACOTHERAPY AMONG PATIENTS DIAGNOSED WITH DEPRESSION  
Hou X, Washington State University, Spokane, WA, USA

PMH37  
IMPROVEMENT OF ANTI-DEPRESSIVE THERAPY QUALITY AND PERSISTENCY BY CORRESPONDENCE COURSE FOR GPS (RESULTS FROM THE IMPROVE-D STUDY)  

PMH38  
CLINICAL COMPARABILITY OF SCHIZOPHRENIA PATIENTS SERVED AT TWO PUBLIC SETTINGS: VETERANS AFFAIRS (VA) AND NON-VA MEDICAID  
Ascher-Svanum H, Zhu B, Stensland MD, Eli Lilly and Company, Indianapolis, IN, USA; Ohio University, Athens, OH, USA

PMH39  
BASELINE COMPARISON OF PATIENTS WITH SCHIZOPHRENIA USING OLANZAPINE, RISPERIDONE AND TYPICAL ANTI-psychotics IN CALIFORNIA MEDICAID PROGRAM  
Mulani P, Gibson PJ, McCombs J, University of Southern California, Los Angeles, CA, USA; Eli Lilly and Company, Indianapolis, IN, USA

PMH40  
THE IMPACT OF SECOND-GENERATION ANTI-psychotics IN BIPOLAR PATIENTS IN THE CALIFORNIA MEDICAID PROGRAM  
Sterling KL, McCombs J, University of Southern California, Los Angeles, CA, USA
PMH41 REDUCTION IN LONG-ACTING BENZODIAZEPINE THERAPY AND ASSOCIATED FRACTURES IN ELDERLY MEDICAID PATIENTS
Dodd MA, Shah BM, Gupchup GV, Anderson JR, The University of New Mexico, Albuquerque, NM, USA

PMH42 FROM CONVENTIONAL ANTI精神病CITY TO ATYPICALS AND BACK: DYNAMIC PROCESSES IN THE DIFFUSION OF NEW MEDICATIONS
Leslie DL, Rosenheck R, Yale University School of Medicine, West Haven, CT, USA

PMH43 THE IMPACT OF A FORMULARY EXPANSION TO INCLUDE ADDITION OF SECOND-GENERATION ANTI精神病CITY MEDICATIONS ON THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA
Mulani P, McCombs J, University of Southern California, Los Angeles, CA, USA

PMH44 SURVEY AND STATED PREFERENCE TECHNIQUES FOR ESTIMATING THE DEMAND FOR ALCOHOLISM MEDICATIONS
Mark TL1, Bransberger P2, Kranzler HR2, 1The Medstat Group, Washington, DC, USA; 2Westat, Rockville, MD, USA; 1University of Connecticut School of Medicine, Farmington, CT, USA

PMH45 THE EFFECT OF SCHIZOPHRENIA SYMPTOMS ON EMPLOYMENT OUTCOMES
Clark TJ1, Harris SD2, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

PMH46 MEDICATION TREATMENT PATTERNS FOLLOWING THE INITIATION OF OLanzAPINE VERSUS RISPERIDONE IN A NATURALISTIC SETTING
Zhao Z1, Lage MJ2, Tunis SL2, Eli Lilly and Company, Indianapolis, IN, USA; 1HealthMetrics Outcomes Research, L.L.C, Groton Long Point, CT, USA

EAR, EYE & SKIN DISEASES/DISORDERS

Clinical Outcomes Presentations

PES1 QUANTIFYING POTENTIALLY INAPPROPRIATE OPHTHALMIC BETA-BLOCKER USE IN THE MANAGEMENT OF GLAUCOMA
Spooner JJ1, Barron JJ2, Ikeda L1, Cockerham T2, Waugh WJ3, Mozaffari E4, 1Health Core, Inc, Newark, DE, USA; 2Pharmacia Corp, Peapack, NJ, USA; 3WellPoint Pharmacy Management, West Hills, CA, USA

Economic Outcomes Presentations

PES2 A DECISION-ANALYTIC MODEL TO COMPARE THE COST OF METHYL AMINOLEVULINATE PHOTODYNAMIC THERAPY WITH STANDARD TREATMENTS IN THE UK FOR DIFFICULT-TO-TREAT BASAL CELL CARCINOMA AND ACTINIC KERATOSIS
Aristides M1, Tilden D2, Robinson P2, Weston A2, Davey P3, Aldridge G4, 1Medical Technology Assessment Group, London, UK; 2Medical Technology Assessment Group, Chatswood West, NSW, Australia

PES3 TOPICAL CORTICOSTEROID AND PHYSICIAN VISIT UTILIZATION AND COSTS IN PATIENTS WITH ATOPIC DERMATITIS
Kahler KH1, Pinkston P1, Freimark N2, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 1non-affiliated, Lakewood, NJ, USA

PES4 INFORMAL CAREGIVERS COSTS IN THE ELDERLY US POPULATION: A MULTIVARIATE REGRESSION MODEL OF THE VISUALLY IMPAIRED VERSUS UNIMPAIRED
Shih YCT1, Lustig SP2, 1MEDTAP International Inc, Bethesda, MD, USA; 2Pfizer Inc, Groton, CT, USA

PES5 COST ANALYSIS OF ISOTRETINOIN FOR SEVERE RECASCITRANT NODULAR ACNE
Neary M1, Peters JC2, Smith MW2, Hong J1, Ellis CN1, 1Hoffman La Roche, Nutley, NJ, USA; 2Medstat Group Inc, Washington, DC, USA; 1University of Michigan Medical School, Ann Arbor, MI, USA

Health Policy Presentations

PES6 COST EFFECTIVENESS OF PHOTODYNAMIC THERAPY (PDT) WITH VERTEPORFIN IN THE UK
Smith DH1, Fenn P2, Drummond M3, 1Kaiser Permanente Center for Health Research, Portland, OR, USA; 2Nottingham University, Nottingham, UK; 3Innovus Research (UK) Ltd. and University of York, Heslington, York, UK

PES7 ECONOMIC EVALUATION OF PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR PREDOMINANTLY CLASSIC, SUBFOVEAL CNV SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Lees M1, Davey P2, Aldridge G3, Schulz M3, Aristides M1, 1Medical Technology Assessment Group, Chatswood West, NSW, Australia; 2Medical Technology Assessment Group, London, UK

Quality of Life Presentations

PES8 THE PATIENTS’ PERCEPTION OF THEIR PSORIASIS AND ITS TREATMENT THROUGH A DIARY
Taieb C1, Myeon E2, Pharmacoeconomics Programs, bioMérieux-Pierre Fabre, Boulogne Billancourt, France

PES9 PSORIASIS AND EVERYDAY LIFE: FIRST RESULTS
Taieb C1, Myeon E2, Pharmacoeconomics Programs, bioMérieux-Pierre Fabre, Boulogne Billancourt, France

PES10 THE PSORIASIS MANAGEMENT DURATION INDUCED DIFFERENCES IN THE DISABILITY’S PERCEPTION
Taieb C1, Myeon E2, Pharmacoeconomics Programs, bioMérieux-Pierre Fabre, Boulogne Billancourt, France

PES11 FUNCTIONAL LIMITATIONS IN THE US ELDERLY POPULATION WITH VARYING LEVELS OF VISUAL IMPAIRMENT
Susan LP1, Shih YCT2, Prasad M3, 1Pfizer Inc, Groton, CT, USA; 2MEDTAP International Inc, Bethesda, MD, USA

GASTROINTESTINAL DISEASES/DISORDERS

Clinical Outcomes Presentations

PGI1 EFFECTIVENESS OF MEDICAL INTERVENTIONS IN PATIENTS WITH SYMPTOMS OF GERD – A SYSTEMATIC REVIEW
Edwards S1, Wahlqvist P2, 1AstraZeneca UK Ltd, Hertfordshire, UK; 2AstraZeneca R&D Mölndal, Mölndal, Sweden

PGI2 THERAPEUTIC COMPARABILITY OF PROTON PUMP INHIBITORS von Scheele B1, Sherrill B2, Richter A2, Devlin P2, RTi Health Solutions, Research Triangle Park, NC, USA

Economics Outcomes Presentations

PGI3 IMPACT OF PROTON PUMP INHIBITOR UTILIZATION PATTERNS ON GASTROESOPHAGEAL REFLUX DISEASE-RELATED COSTS
Hall JA1, Dodd SL2, Durkin M1, Sloan S1, Ingenix Pharmaceutical Services, Eden Prairie, MN, USA; 1Janssen Pharmaceutical, Titusville, NJ, USA

PGI4 PROTON PUMP INHIBITOR RETROSPECTIVE DATABASE PHARMACY COST AND UTILIZATION STUDY
Kiplew LA1, Browne BA2, Tabor P2, Jackmiec J3, Woodward B1, Thompson A1, 1Scott & White Health Plan, Temple, TX, USA; 2Janssen, Titusville, NJ, USA

PGI5 COST-EFFECTIVENESS OF IV PPI’S IN THE TREATMENT OF NON-VARICEAL UPPER GI BLEEDING FOLLOWING URGENT ENDOSCOPY
Herba K1, Barkun A2, Kennedy WA3, Fallone CA2, RUGBE Investigators A1, 1McGill University Health Centre, Montreal, QC, Canada; 2University of Montreal, Montreal, QC, Canada
EFFECT OF POSTOPERATIVEILEUS ON LENGTH OF STAY IN COLECTOMY
Saravane C, Dalal M, University of Illinois at Chicago, Chicago, IL, USA

ECONOMIC OUTCOMES OF EMPLOYER BENEFICIARIES TREATED FOR IRITRABLE BOWEL SYNDROME (IBS)
Leong SA1, Barghout V1, Birnbaum HG1, Ben-Hamadi R1, Thibeault C1, Frech P1, Ofman J1, ‘Analysis Group/Economics, Cambridge, MA, USA; ‘Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; ‘Cedars-Sinai/Zynx Health Inc, Los Angeles, CA, USA

A COST ANALYSIS OF DIAGNOSIS AND TREATMENT STRATEGIES IN PATIENTS WITH SYMPTOMS OF POUCHITIS
Shermock KM1, Shen B, Lashner BA, Achkar JP, The Cleveland Clinic Foundation, Cleveland, OH, USA

THE EFFECTIVE USE OF INTRAVENOUS PROTON PUMP INHIBITOR CONTINUOUS INFUSION (IV PPI) ADMINISTERED PRIOR TO ENDOSCOPY IN THE TREATMENT OF PATIENTS WITH NON-VARICEAL UPPER GI BLEEDING
Barkun A1, Herba K1, Kennedy WA1, Fallone CA1, RUGBE Investigators A1, ‘McGill University Health Centre, Montreal, QC, Canada; ‘University of Montreal, Montreal, QC, Canada

PHARMACY DISPENSING PATTERNS, COST AND HEALTHCARE UTILIZATION: A STUDY OF LANOSPORAZOLE
Johnson ML1, Beyth R, Houston Center for Quality of Care and Utilization Studies, Houston, TX, USA

EFFECT OF RABEPRAZOLE ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS REPORTING INEFFECTIVE RELIEF WITH PRIOR OMEPRAZOLE OR LANOSPORAZOLE THERAPY
Girts TK1, Siddique RM, Jokubaitis LA, Janssen Pharmaceutica Inc., Titusville, NJ, USA

FACTOR STRUCTURE AND FURTHER VALIDATION OF THE GASTROESOPHAGEAL REFLUX DISEASE (GERD) SYMPTOM ASSESSMENT SCALE
Damiano A1, Siddique R1, Xu X1, Imeokparia A1, ‘Covance Health Economics and Outcomes Services Inc, Gaithersburg, MD, USA; ‘Janssen Pharmaceutica Inc, Titusville, NJ, USA

USE OF NONSTEROIDAL ANTI-INFLAMMATORY AGENTS IN PATIENTS AT HIGH RISK FOR GASTROINTESTINAL SIDE EFFECTS IN A VETERANS AFFAIRS MEDICAL CENTER
Harris CL1, Raisch DW1, VA Cooperative Studies Program, Albuquerque, NM, USA

ASSESSMENT OF USE OF THE VETERANS AFFAIRS’ CRITERIA FOR NONSTEROIDAL ANTI-INFLAMMATORY AGENTS
Harris CL1, Raisch DW1, VA Cooperative Studies Program, Albuquerque, NM, USA

THE EFFECT OF ANTIBIOTIC USE ON RETURN VISITS FOR ACUTE RESPIRATORY TRACT INFECTIONS
Fedorowicz F1, Gardella P, Rubin S, Share D, Blue Cross Blue Shield of Michigan, Detroit, MI, USA

RETROSPECTIVE ANALYSIS OF IMIPENEM/CILASTIN VERSUS PIPRACILLIN/TAZOBACTAM IN TREATMENT OF INFECTED NEUTROPenic PATIENTS
Egan TF1, McGhan WF1, ‘Kennedy Health System and the University of Sciences in Philadelphia, Stratford, NJ, USA; ‘The University of the Sciences in Philadelphia, Philadelphia, PA, USA

COST-EFFECTIVENESS OF VACCINE DEVELOPMENT AND ENVIRONMENTAL CONTROL AGAINST DENGUE IN SOUTHEAST ASIA
Suaya JA1, Shepard DS1, Halstead S1, ‘Brandeis University, Waltham, MA, USA; ‘Rockefeller Foundation, Rockville, MD, USA

ECONOMIC IMPACT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION ON HEALTHCARE RESOURCE UTILIZATION AND COSTS IN THE UNITED STATES
Paramore C1, Ciuryla V1, Ciesla G1, Liu Z2, ‘MEDTAP International, Bethesda, MD, USA; ‘Wyeth-Ayerst Research, Philadelphia, PA, USA

COST-EFFECTIVENESS OF VACCINATING ADULT CLOSE CONTACTS WITH BOOSTRIX®
Kornfield TB1, Botteman MF2, Pashos C1, ‘Abt Associates Clinical Trials, Bethesda, MD, USA; ‘Abt Associates Clinical Trials, Cambridge, MA, USA

DIRECT MEDICAL COSTS OF MANAGING AN EPISODE OF RESPIRATORY SYNCYTIAL VIRUS (RSV) COMMUNITY ACQUIRED PNEUMONIA (CAP) IN U.S. ADULTS
O’Brien J, Patrick A, Duran P, Klittich W, Lee K, Caro J1, Caro Research Institute, Concord, MA, USA

EVALUATION OF THE COST-EFFECTIVENESS OF AZITHROMYCIN VERSUS AMOXICILLIN, AMOXICILLIN/CLAVALANULATE, AND CLARITHROMYCIN FOR THE TREATMENT OF ACUTE SINUSITIS IN A LARGE MANAGED CARE DATABASE
Hamnett J1, Wilson J1, Cheng R1, ‘Pfizer, Inc, New York, NY, USA; ‘Protocare Sciences Inc, Santa Monica, CA, USA

INCIDENCE AND RELATED HEALTHCARE RESOURCE USE OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN A HIGH-RISK ADULT POPULATION: A CLAIMS DATABASE ANALYSIS
Iloeje UH1, Wu W1, Wu Y1, ‘Bristol Myers Squibb Company, Wallingford, CT, USA; ‘Bristol Myers Squibb Company, Princeton, NJ, USA

LONG-TERM ECONOMIC CONSEQUENCES OF ORGAN DYSFUNCTION FOLLOWING HOSPITAL DISCHARGE OF SEPSIS PATIENTS
Roberts CS1, Chang L, Bakst AW1, Mera RM, GlaxoSmithKline, Collegeville, PA, USA

COST-UTILITY OF SELECTIVE BUPRENORPHINE SUBSTITUTION FOR METHADONE MAINTENANCE IN PREVENTING HIV TRANSMISSION
Wall MJ1, Pollack HA1, ‘University of Michigan and Pfizer Inc, Ann Arbor, MI, USA; ‘University of Michigan, Ann Arbor, MI, USA

INITIAL ANTIMICROBIAL THERAPY AND OUTCOMES IN PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP)
Onesirosan PT1, Gutierrez B, Gaylord-Miles B, Hatch V, Premier, Inc, Charlotte, NC, USA

COSTS OF TREATMENT FOR AMBULATORY LOWER RESPIRATORY TRACT INFECTION IN QUEBEC SENIORS
Kennedy WA1, Laurier C1, Paré M1, Philibert L1, University of Montreal, Montreal, QC, Canada

THE IMPACT OF ANTIBIOTIC SELECTION ON TREATMENT OUTCOMES FOR ACUTE OTITIS MEDIA
Ayyar Krishnan A1, Christensen DB1, University of North Carolina, Chapel Hill, NC, USA

HEALTH RESOURCE UTILIZATION IN THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
Ahn J1, Mullins CD1, Shaya FT1, Merchant S1, Corcoran G1, Church D2, ‘University of Maryland, Baltimore, MD, USA; ‘Bayer Pharmaceutical Corporation, West Haven, CT, USA

ECONOMIC OUTCOMES PRESENTATIONS
PINF3 COST-EFFECTIVENESS OF VACCINE DEVELOPMENT AND ENVIRONMENTAL CONTROL AGAINST DENGUE IN SOUTHEAST ASIA
Suaya JA1, Shepard DS1, Halstead S1, ‘Brandeis University, Waltham, MA, USA; ‘Rockefeller Foundation, Rockville, MD, USA

PINF4 ECONOMIC IMPACT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION ON HEALTHCARE RESOURCE UTILIZATION AND COSTS IN THE UNITED STATES
Paramore C1, Ciuryla V1, Ciesla G1, Liu Z2, ‘MEDTAP International, Bethesda, MD, USA; ‘Wyeth-Ayerst Research, Philadelphia, PA, USA

PINF5 COST-EFFECTIVENESS OF VACCINATING ADULT CLOSE CONTACTS WITH BOOSTRIX®
Kornfield TB1, Botteman MF2, Pashos C1, ‘Abt Associates Clinical Trials, Bethesda, MD, USA; ‘Abt Associates Clinical Trials, Cambridge, MA, USA

PINF6 DIRECT MEDICAL COSTS OF MANAGING AN EPISODE OF RESPIRATORY SYNCYTIAL VIRUS (RSV) COMMUNITY ACQUIRED PNEUMONIA (CAP) IN U.S. ADULTS
O’Brien J, Patrick A, Duran P, Klittich W, Lee K, Caro J1, Caro Research Institute, Concord, MA, USA

PINF7 EVALUATION OF THE COST-EFFECTIVENESS OF AZITHROMYCIN VERSUS AMOXICILLIN, AMOXICILLIN/CLAVALANULATE, AND CLARITHROMYCIN FOR THE TREATMENT OF ACUTE SINUSITIS IN A LARGE MANAGED CARE DATABASE
Hamnett J1, Wilson J1, Cheng R1, ‘Pfizer, Inc, New York, NY, USA; ‘Protocare Sciences Inc, Santa Monica, CA, USA

PINF8 INCIDENCE AND RELATED HEALTHCARE RESOURCE USE OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN A HIGH-RISK ADULT POPULATION: A CLAIMS DATABASE ANALYSIS
Iloeje UH1, Wu W1, Wu Y1, ‘Bristol Myers Squibb Company, Wallingford, CT, USA; ‘Bristol Myers Squibb Company, Princeton, NJ, USA

PINF9 LONG-TERM ECONOMIC CONSEQUENCES OF ORGAN DYSFUNCTION FOLLOWING HOSPITAL DISCHARGE OF SEPSIS PATIENTS
Roberts CS1, Chang L, Bakst AW1, Mera RM, GlaxoSmithKline, Collegeville, PA, USA

PINF10 COST-UTILITY OF SELECTIVE BUPRENORPHINE SUBSTITUTION FOR METHADONE MAINTENANCE IN PREVENTING HIV TRANSMISSION
Wall MJ1, Pollack HA1, ‘University of Michigan and Pfizer Inc, Ann Arbor, MI, USA; ‘University of Michigan, Ann Arbor, MI, USA

PINF11 INITIAL ANTIMICROBIAL THERAPY AND OUTCOMES IN PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP)
Onesirosan PT1, Gutierrez B, Gaylord-Miles B, Hatch V, Premier, Inc, Charlotte, NC, USA

PINF12 COSTS OF TREATMENT FOR AMBULATORY LOWER RESPIRATORY TRACT INFECTION IN QUEBEC SENIORS
Kennedy WA1, Laurier C1, Paré M1, Philibert L1, University of Montreal, Montreal, QC, Canada

PINF13 THE IMPACT OF ANTIBIOTIC SELECTION ON TREATMENT OUTCOMES FOR ACUTE OTITIS MEDIA
Ayyar Krishnan A1, Christensen DB1, University of North Carolina, Chapel Hill, NC, USA

PINF14 HEALTH RESOURCE UTILIZATION IN THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
Ahn J1, Mullins CD1, Shaya FT1, Merchant S1, Corcoran G1, Church D2, ‘University of Maryland, Baltimore, MD, USA; ‘Bayer Pharmaceutical Corporation, West Haven, CT, USA
Quality of Life Presentations

PIN17 PRELIMINARY RESULTS OF A U.S.-BASED STUDY TO VALIDATE THE ACUTE BRONCHITIS SYMPTOM SEVERITY SCALE
Leidy NK1, Margolis MK2, Merchant S3, Gondek K4, Li-McLeod J5, Kiskin A6, Choudhri S7, Church D8, MEDTAP International, Bethesda, MD, USA; Bayer Pharmaceutical Corporation, West Haven, CT, USA

Health Policy Presentations

PIN20 PHYSICIAN PRESCRIBING PATTERNS FOR PEDIATRIC OTITIS MEDIA IN AMBULATORY PATIENTS
Rahman AM1, Feldhaus J1, Lawrence L2, Rappaport H2, Hoffman LaRoche Inc, Nutley, NJ, USA; MEDTAP, Seattle, WA, USA; MEDTAP International, Inc, Bethesda, MD, USA; North Shore University Hospital, Manhasset, NY, USA

Economic Outcomes Presentations

PMW2 ECONOMIC ANALYSIS OF SILDENAFIL CITRATE ADD-ON TO TREAT SSRI-INDUCED ERECTILE DYSFUNCTION
Nunberg HG9, Duttagupta S2, University of New Mexico, Albuquerque, NM, USA; Pfizer Pharmaceuticals Group, Pfizer Inc, New York, NY, USA

Quality of Life Presentations

PIN15 PREFERENCES AND WILLINGNESS-TO-PAY FOR HEALTH STATES PREVENTED BY PNEUMOCOCCAL CONJUGATE VACCINE
Proser LA1, O’Brien MA1, Ray GT2, Santoli JM3, Lieu TA1, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA, USA; Kaiser Permanente, Oakland, CA, USA; Centers for Disease Control and Prevention, Atlanta, GA, USA

NEUROLOGICAL/PAIN DISORDERS

Economic Outcomes Presentations

PNP1 SOCIO-ECONOMIC IMPACT OF MIGRAINE IN FRANCE IN 2000
Pradalier A1, Auray JP2, Duro G3, Chazot G4, Dartigues JP5, Henry P6, Lanteri-Minet M1, El Hasnaoui A2, Gaudin AP1, Hospital Louis Mourier, Colombes, France; Université Claude Bernard Lyon, Lyon, France; Hospital Cardio Vasculaire et Neurologique, Bron, France; Université Bordeaux II, Bordeaux, France; Hospital Pellegrin, Bordeaux, France; CHU de Nice, Nice, France; Hospital Roger Salengro, Lille, France; Laboratoire Glaxo Wellcome, Marly le Roi, France

Clinical Outcomes Presentations

PMW1 LIFE EXPECTANCY PREDICTION OF HRT FOR PRIMARY PREVENTION STRATEGIES IN POST-MENOPAUSAL WOMEN
Perreault S1, Levinton C2, Montreal University, Montreal, QC, Canada

PNP2 COST-EFFECTIVENESS OF RAPID MRI VERSUS LUMBAR X-RAY AS THE INITIAL INVESTIGATION FOR PRIMARY CARE PATIENTS WITH LOW BACK PAIN: A RANDOMIZED CONTROLLED TRIAL
Hollingworth W1, Jarvik J2, Gray DT3, Deyo RA1, Martin BI4, Sullivan SD5, University of Cambridge, Cambridge, UK; University of Washington, Seattle, WA, USA

Health Outcomes Presentations

PIN18 THE ASSOCIATION BETWEEN HEALTH RELATED QUALITY OF LIFE AND ADHERENCE TO THERAPY IN HEPATITIS C
Green J1, Wintfeld N2, Barker C3, Revicki D4, Hoffman LaRoche Inc, Nutley, NJ, USA; MEDTAP, Seattle, WA, USA; MEDTAP International, Inc, Bethesda, MD, USA; North Shore University Hospital, Manhasset, NY, USA

PIN19 PRESCRIBING DECISIONS IN A UTILITY MODEL
Shaya FT1, Mullins CD2, Ahn J3, Merchant S4, Corcoran G5, Church D6, University of Maryland, Baltimore, MD, USA; Bayer Pharmaceutical Corporation, West Haven, CT, USA

PIN21 SECOND-LINE THERAPY FOR OUTPATIENT TREATMENT FOR COMMUNITY-ACQUIRED PNEUMONIA
Singer ME1, Jaffe DH2, Case Western Reserve University, Cleveland, OH, USA

PIN22 PATIENT TREATMENT ACCORDING TO PRACTICE GUIDELINES IN COMMUNITY HOSPITALS COMPARED TO TEACHING HOSPITALS IN THE COMMUNITY-ACQUIRED PNEUMONIA (CAP) PROJECT
Chakledkaeu U1, Hopef A2, Goad JA3, Kamath TV4, Johnson KA5, University of Southern California, Los Angeles, CA, USA; AmeriNet, St. Louis, MO, USA; Bristol-Myers Squibb, Princeton, NJ, USA

PIN23 THE IMPACT OF PHYSICIAN REPORTED RISK FACTORS ON HOSPITALIZATION RATES FOR INFANTS ON PALIVIZUMAB THERAPY
Marks AS1, Berger J2, Slezak J3, Johnson KE4, Caremark, Inc, Northbrook, IL, USA

PIN24 WHAT IS THE VALUE OF WARD SUPPLY DATA FOR MONITORING ANTI-BIOTIC USE IN HOSPITAL?
Ofori BO1, Davey PG2, Ninewells Hospital and Medical School, Dundee, UK; University of Dundee, Dundee, UK

PIN25 COST-EFFECTIVENESS OF NEW RAPID SCREENING TECHNOLOGIES FOR GONORRHEA IN URBAN EMERGENCY ROOM DEPARTMENTS
Alderton JE1, Goldie SJ2, Harvard University, Boston, MA, USA

Clinical Outcomes Presentations

PMW1 LIFE EXPECTANCY PREDICTION OF HRT FOR PRIMARY PREVENTION STRATEGIES IN POST-MENOPAUSAL WOMEN
Perreault S1, Levinton C2, Montreal University, Montreal, QC, Canada
Economic Outcomes Presentations

**PUK3** COST EFFECTIVENESS OF INTENSIVE BEHAVIORAL MANAGEMENT VERSUS DDAVP IN PRIMARY NOCTURNAL ENURESIS

Fegan TE, McGhan WF; ‘Kennedy Health System and the University of Sciences in Philadelphia, Stratford, NJ, USA; ‘Philadelphia College of Pharmacy, Philadelphia, PA, USA

**PUK4** AN ECONOMIC MODEL OF OVERACTIVE BLADDER IN NORWAY


**PUK5** INCIDENCE AND COST ASSOCIATED WITH PHARMACOLOGICAL TREATMENT FOR EMPLOYEES DIAGNOSED WITH URINARY AND OVERACTIVE BLADDER DISORDERS

Muchmore L, Williamson TE, Gardner H; ‘Options and Choices, Cheyenne, WY, USA; ‘Pharmacia, Peapack, NJ, USA

**PUK6** A BUDGET IMPACT ANALYSIS OF EARLY REFERRAL TO A NEPHROLOGIST FOR ELDERLY MEDICARE PATIENTS WITH END-STAGE RENAL DISEASE

Shih YCT, Guo AM, Prasad M; ‘Just PM, ‘MEDTAP International Inc, Bethesda, MD, USA; ‘Baxter Healthcare Corporation, Deerfield, IL, USA

Quality of Life Presentations

**PUK7** DEVELOPMENT OF THE SYMPTOM FREQUENCY AND BOTHERSOMENESS SCALE FOR STRESS URINARY INCONTINENCE (SFB-SUI)

Garvant S, Bowman L, Buesching D, Patrick D, Martin M, ‘Eli Lilly and Company, Windlesham, UK; ‘Eli Lilly and Company, Indianapolis, IN, USA; ‘University of Washington, Seattle, WA, USA; ‘Health Research Associates, Seattle, WA, USA

**PUK8** VALIDATION OF THE PERCEPTION OF BLADDER CONDITION MEASURE IN OVERACTIVE BLADDER

Coyne K, Matza LS, MEDTAP International, Inc, Bethesda, MD, USA

**PUK9** VALIDATION OF THE URGENCY PERCEPTION SCALE

Cardozo L, Coyne KS, Versi E; ‘Kings College Hospital, London, UK; ‘MEDTAP International, Bethesda, MD, USA; ‘Pharmacia Corporation, Peapack, NJ, USA

**PUK10** ASSESSING PATIENT SATISFACTION IN A DIALYSIS POPULATION

Cafarelli M, Chapman MM, Brown RH, Zager PG, ‘New England Medical Center, Boston, MA, USA; ‘Dialysis Clinic, Inc, Albuquerque, NM, USA

**PUK11** EFFECTS OF LONG-TERM TOLTERODINE TREATMENT ON PHYSICAL AND SYMPTOM ASPECTS OF HEALTH-RELATED QUALITY OF LIFE IN OVERACTIVE BLADDER PATIENTS

Okano GJ, Pleil AM, Reese PR; ‘Kelleher CI, ‘Strategic Outcomes Services of CareScience, Research Triangle Park, NC, USA; ‘Pharmacia Limited, High Wycombe, Bucks, UK; ‘Guys and St. Thomas’ NHS Trust, London, UK

**PUK12** HOW RESPONSIVE IS THE OVERACTIVE BLADDER QUESTIONNAIRE (OAB-Q) TO CHANGES IN URGENCY, FREQUENCY, AND INCONTINENCE?


**Registration Deadline:** WEDNESDAY, MAY 1, 2002
The discounted room rate for ISPOR meeting attendees is $165.00 for single occupancy and $175.00 for double occupancy. For hotel reservations, please call: 1-800-233-1234 or 1-703-418-1234. The deadline for hotel reservations is April 19, 2002. The Hyatt Regency Crystal City offers hotel guests complimentary shuttle service to and from Washington National Airport and the METRO subway.

EXHIBITOR INFORMATION

Exhibits will be on view from 10:00am Monday, May 20 until 4:00pm Tuesday, May 21. No general sessions are scheduled during exhibit hours. Therefore, the exhibitors are not competing with programming during exhibit hours. To increase exposure, the exhibit programs are held concurrently with contributed poster presentations in the same Exhibit Hall permitting integration of exhibits and poster presentations. The Exhibitors Open House & Reception will be held in the Exhibit Hall in addition to all refreshment and lunch breaks on both Monday and Tuesday. The fee to exhibit is $2000 for an 8’ x 10’ booth.

EXHIBIT HOURS
MONDAY, MAY 20
7:00am-10:00am Exhibit Set-up
10:00am-10:30am Break
12:00pm-1:30pm Lunch
6:00pm-8:00pm Exhibitors’ Open House & Reception

TUESDAY, MAY 21
9:30am-10:00am Break
12:00pm-1:30pm Lunch
4:00pm-6:00pm Exhibit Dismantle

SPONSORSHIP OPPORTUNITIES

We also invite your organization to be an official sponsor of one or more events at the ISPOR Seventh Annual International Meeting and gain more visibility. The following ISPOR Seventh Annual International Meeting Events are available for sponsorship:

☐ COFFEE BREAK Monday, May 20 1,500 US $
☐ COFFEE BREAK Tuesday, May 21 1,500 US $
☐ LUNCH Monday, May 20 2,500 US $
☐ LUNCH Tuesday, May 21 2,500 US $
☐ EXHIBITORS’ OPEN HOUSE RECEPTION Monday, May 20 8,000 US $
☐ STUDENT “ICEBREAKER” RECEPTION Sunday, May 19 3,000 US $
☐ REGISTRATION TOTES 8,000 US $

CONTACT INFORMATION

www.ispor.org
or contact
Nadia Naaman
Director, Marketing
and Member Services
ISPOR
3100 Princeton Pike
Bldg 3, Suite D
Lawrenceville, NJ
08648 USA
Tel:+609-219-0773 ext.11
or nnaaman@ispor.org

For more information visit
www.ispor.org or contact
Nadia Naaman
Director, Marketing
and Member Services
Tel:+609-219-0773 ext.11
or nnaaman@ispor.org

ISPOR PROFESSIONAL RECRUITMENT ASSISTANCE PROGRAM

The Professional Recruitment Assistance Program Center (PRAP) provides participants with a CONFIDENTIAL, EFFICIENT and PROFESSIONAL service that pairs individuals seeking positions with employers who have available positions. It includes:

- Listings of available positions
- Listings of qualified candidates
- A mailbox system for applicants and employers
- A 1/4 page announcement in the final program (if received before April 29, 2002)
- Private rooms for interviewing
- Company listing on ISPOR Web Site

FEE Candidates: (members or meeting registrants) FREE of charge
Employers: $1000 USD for the first position and $500 USD for each additional position advertised by the same employer.

For more information visit
www.ispor.org or contact
Nadia Naaman
Director, Marketing
and Member Services
Tel:+609-219-0773 ext.11
or nnaaman@ispor.org

SOLD! http://www.ispor.org/meetings/va0502/exhibitors.htm

ADVERTISEMENT OPPORTUNITIES

Use the ISPOR Seventh Annual Meeting final program to place your advertisement.

RATES:
☐ FULL PAGE 7.5 x 10 inches: $1000
☐ HALF PAGE 7.5 x 4.75 inches: $700
☐ QUARTER PAGE 3.25 x 4.75 inches: $450

For more information visit
www.ispor.org or contact
Nadia Naaman
Director, Marketing
and Member Services
Tel:+609-219-0773 ext.11
or nnaaman@ispor.org

http://www.ispor.org/meetings/va0502/sponsor.htm
Please enclose a check payable in US dollars to: International Society for Pharmacoeconomics and Outcomes Research or ISPOR and send to the ISPOR address given below or charge to:

+ **VISA**
+ **MasterCard**
+ **American Express**

**NAME:** AUTHORIZED SIGNATURE:

ACCOUNT NUMBER: EXPIRATION DATE:

Payment must be made in US dollars. Payment may be made by check or travelers check. VISA, MasterCard, or American Express will be charged in US dollars. Signature, account number, and expiration date must be included. Non-US checks written in US$ must be written on banks with a US counterpart. Phone charges will NOT be accepted. If payment is being made by your company, please make sure your name is indicated on the check stub or correspondence.

If ISPOR cannot verify your current membership, you will be charged the non-member registration rate.

*One Day Registration does not include membership benefits.

When you register as a non-member, you receive ISPOR membership and a one-year, hard copy subscription to VALUE IN HEALTH-The Journal of the International Society for Pharmacoeconomics and Outcomes Research. Cancellation fee before May 1, 2002 is US $100. No refunds given after May 1, 2002.

SEND REGISTRATION FORM (OR FAX, IF USING CREDIT CARD) TO:

International Society for Pharmacoeconomics and Outcomes Research
3100 Princeton Pike, Building 3, Suite D, Lawrenceville, NJ 08648 USA Tel: 1-609-219-0773 Fax: 1-609-219-0774 Email: info@ispor.org Internet: www.ispor.org